CURRICULUM VITÆ – Carla Oliveira, BSc, PhD

Name: Carla Isabel Gonçalves de Oliveira
Birth date: March 18, 1973
Institutional address: i3S/Ipatimup Rua Alfredo Allen, 208, 4200-135 Porto, Portugal. Lab 208S4 - 2nd floor
Telephone: +351 225570785 (direct tel. office); +351 220408800 - Ext:6173 (Office 208S2A) & Ext:6172 (Lab)
Telefax: + 351 225570799; **Email:** carlaol@ipatimup.pt
Researcher unique ID: ResearcherID-F-8188-2011; ORCID-0000-0001-8340-2264; Scopus-7102223149
URL for web site: http://www.i3s.up.pt/research-groups/cancer/expression-regulation-cancer
Researcher unique ID: ResearcherID-F-8188-2011; ORCID-0000-0001-8340-2264; Scopus-7102223149

Education and Training

- *2002/03/15:* Ph.D. in Human Biology, GABBA Ph.D. Program, Medical Fac, Univ. Porto, Portugal
- *2000-2002:* Visiting Ph.D. student, Ipatimup-Institute of Molecular Pathology and Immunology (Raquel Seruca Lab), UPorto, PT
- *1999-2000:* Ph.D. student, CIMR - Cambridge Institute for Medical Research (Carlos Caldas Lab), Cambridge Univ., UK
- *1998-1999:* Graduate Program in Areas of Basic and Applied Biology - GABBA Ph.D. Program
- *1995-1996:* Degree Training at IBILI, Fac. Science and Tech, Univ. Coimbra, Portugal
- *1991-1995:* Biochemistry Degree (4 years undergraduate studies), Faculty of Science and Technology, Univ. Coimbra, Portugal

Fellowships

- *2011-2012:* Sabbatical fellowship (bsab/1311870456/2011) Science and Technology Foundation (FCT), PT
- *2005:* Travel fellowship from European Association for Cancer Research (EACR) to Vancouver, CA
- *2002-2005:* Post-doctoral fellowship (SFRH/BPD/9463/2002), FCT, PT
- *1997-2002:* GABBA Ph.D. Program studentship (PRAXIS XXI/BD/13378/97), FCT, PT
- *1997:* FCT Trainee fellowship (PRAXIS XXI), Cancer Genetics Group - Ipatimup, Porto, PT

Current and Previous Positions

- *2013-present:* Principal Investigator, Expression Regulation in Cancer Group, i3S/Ipatimup, Porto, PT
- *2013-present:* Founder/CEO Bioinformatics Start-up Company Bioinf2Bio, Porto, PT | http://bit.ly/2lq5DY8
- *2011-2012:* Guest Scientist, Max Planck Institute for Developmental Biology, Tuebingen, DE
- *2011:* Tenure-track Group Leader, Ipatimup, Porto, PT
- *2008/01:* Financially Independent Researcher in Cancer Genetics Group, IPATIMUP, Porto, Portugal
- *2006-present:* Invited Professor, Dept. Pathology/Oncology, Medical Faculty UPorto, PT | www.med.up.pt
- *2005-2010:* Auxiliary Investigator, Cancer Genetics Group, Ipatimup, Porto, PT
- *2005-present:* Consultant for cancer-associated syndromes, Ipatimup Diagnostics Unit
- *2002-2005:* Auxiliary Professor of Biochemistry, Univ. Fernando Pessoa, Porto, PT
- *2004-2005:* Postdoc fellow (D Huntsman's lab), Pathol. Dept. Laboratory Medicine, UBC, Vancouver, CA
- *2002-2004:* Postdoc fellow (R Seruca's lab), Cancer Genetics Group, Ipatimup, Porto, PT

Institutional Responsibilities

- *2013-present:* Member of the Scientific Committee of Ipatimup and i3S, Porto, PT
- *2008-present:* Member of the Advisory Board of 3 Postdoc fellows and 6 Ph.D. students

Teaching Activities

- *2016:* Faculty, Univ. Aveiro, "From disease to mechanisms". iBiMED Inter. Adv. Training School, *PT*
- *2016:* Faculty, Univ. Minho, "Expression regulation in cancer", Epigenetics Course, PT
- *2016:* Faculty and Organizer, Univ. Residential Centre Bertinoro, "Hereditary diffuse gastric cancer", *European Society* of Human Genetics-ESHG course 1st Spring Course in Hereditary Cancer Genetics, IT

- *2014-present:* Faculty, Univ. Minho, "Functional genomics", Cancer therapy Course, PT
- *2011-present:* Faculty, Ipatimup, "Genomics and Transcriptomics", Workshop Cancer Research. Porto, PT
- *2013: Faculty,* IMMS-Guadalajara, "From disease to mechanisms", Doctoral Prog Hum. Genet, MEX
- *2005-present:* Faculty, GABBA Ph.D. Program – UPorto, "Oncobiology" Course, PT
- *2002-present:* Faculty, Masters and Ph.D. Programs – Med. Fac. UPorto, "Mechanisms of disesase", PT
- *1995/1996:* Monitor (volunteer), practical lessons of Molecular Biology delivered to of Biochemistry and Biology undergraduate students, Univ. Coimbra

Commissions of trust

- 2017-2020: **Chair of the Scientific Committee,** SPGH 2017 | http://spgh.net/reuniao-anual/21a-reuniao-2/
- 2017- 2022: **Deputy Secretary General**, Executive Board ESHG - European Society of Human Genetics
- *2017-2022:* **Scientific Programme Committee Member**, ESHG | https://www.eshg.org/spc.0.html
- 2017 -2018: **Scientific Programme Committee Member**, XLI Jornadas Portuguesas de Genética SPG | https://jornadasgenetica17.wixsite.com/ibimed/committees
- 2017: **Scientific Committee Member**, ASPIC - 3rd ASPIC International Congress | http://3rdcongress.aspic.pt/congress-commitees
- *2017-2018:* **Faculty member**, Cancer Genetics group, European Society for Medical Oncology ESMO
- *2017:* **Faculty member**, Inherited Cancer, 25th United European Gastroenterology Week 2017
- *2017:* **Scientific Committee Member**, Conference "Risco Familiar de Cancro" | www.ligacontracancro.pt/risco-familiar-de-cancro
- *2017:* **Scientific Committee Member**, SINAL 2017 8th Meeting on Signal Transduction
- *2016-Present:* **Panel Member**, ClinGen Genomic Clinical Variant Expert Curation Panel for CDH1 gene | www.clinicalgenome.org/working-groups/clinical-domain/sub-groups/cancer/cdh1-expert-panel/
- *2015-2017:* ***Invited participant,*** Oncology at the Limits Conference Series | www.atthelimits.org/oncology
- *2015-2017:* **Scientific Committee Member**, Grupo Español Investig Vesículas Extracelulares, GEIVEX
- *2014-Present:* **Founding Member and National Representative**, European Reference Network on "ERN Genetic tumour risk syndromes - GENTURIS" | www.genturis.eu
- *2014-Present:* **Curator** of the LOVD database on "CDH1" variants
- 2014: **Scientific Committee Member**, ASPIC | 1st ASPIC International Congress
- *2013-Present:* **Founding and Executive Committee Member** of the Consortium GENOME^{Portugal}
- *2013-2017:* **Management Committee Member**, BMBS COST Action BM1202 "Eur Network: Microvesicles and Exosomes in Health & Disease" | http://bit.ly/2k2bKoM
- *2011-present:* **Review Panel Member** of research grants: New Zealand Health Research Council; ICS-Institut Clinique de la Souris, FR; Dutch Cancer Society, NL; Fondation contre le Cancer, BE
- *2011-present:* **Scientific Evaluation Panel Member** of Ph.D. and Post-doc fellowships and "Investigator FCT" applications for FCT-Portuguese Foundation of Science and Technology
- *2010-2017:* **Scientific Programme Committee Member**, SPGH | http://bit.ly/2lnpOVP
- *2010-2013:* **Scientific Programme Committee Member**, ESHG | https://www.eshg.org/spc.0.html
- *1999-Present:* **Founding Member** of the International Gastric Cancer Linkage Consortium

Participation in Scientific Networks

- 2016-2022: Solve-RD Consortium | www.solve-rd.eu/
- *2015-Present:* Grupo Español de Investigación en Vesículas Extracelulares (GEIVEX)
- 2015-*Present* : TRAIN-EV ITN | http://cordis.europa.eu/project/rcn/211790_en.html
- *2014-Present:* ERN Genetic tumour risk syndromes - GENTURIS" | www.genturis.eu
- 2013-2020: GenomePORTUGAL do Roteiro Nacional de Infraestruturas de Investigação
- *2013-2017:* BMBS COST Action BM1202 "European Network on Microvesicles and Exosomes in Health and Disease" (ME-HAD) | www.cost.eu/COST_Actions/bmbs/BM1202

Research Team, Interests and Expertize

Current resident research team: 2 Project Leaders (iFCT); 3 Post-doc, 3 Ph.D. Students, 4 Master Students, 4 research students, 1 Lab Manager.

Research interest: Characterization of noncoding regulatory mechanisms and development of in vivo models for their study. Identification of biomarkers (genotypic and phenotypic) that may help detecting cancer and evaluating treatment response and resistance.

Team expertize: Human genetics, molecular and cell biology, Next Generation Sequencing and Bioinformatics; a strong link with hospitals which provides patients' biological material, and the Industry that co-funds the research.

Funding for Research Projects

PRINCIPAL INVESTIGATOR (PI) (n=19 projects with a total budget of ~2.8M€):

1. Funded by Programa Operacional Competitividade e Internacionalização (through FEDER) and by Fundação para a Ciência e a Tecnologia. "Solving the 3D chromatin structure of CDH1 locus to identify disease-associated mechanisms (3DChroMe)", (POCI-01-0145-FEDER-30164). **2018-2020. BUDGET: € 239.929,80**
2. Funded by Horizon 2020 - Research and Innovation Framework Programme - H2020-SC1-2017-Single-Stage-RTD. "Solving the unsolved Rare Diseases: Hereditary Gastric Cancer" [SolveRD], (Grant nº 779257; 2018-2022). **2018-2021. BUDGET: € 250.000,00**
3. Funded by Programa Operacional Competitividade e Internacionalização, Programa Operacional Regional de Lisboa, Programa Operacional Regional do Algarve (Portugal2020 and H2020, through FEDER) and by Fundação para a Ciência e a Tecnologia. "National Laboratory for Genome Sequencing and Analysis" – (Project reference 22184 – GenomePT). **2017-2020. BUDGET: € 502.219,21 (Co-PI – Carla Oliveira)**
4. Funded by Programme/Call: H2020-MSCA-ITN-2016 - Marie Skłodowska-Curie Innovative Training Networks. "Training in Extracellular vesicles: for benefit in Health & Disease" [TRAIN-EV], (Grant nº 722148). **2017-2021. BUDGET: € 238.356,36. The Beneficiary is Bioinf2Bio a Startup of Ipatimup and Ipatimup is a Affiliated Institution.**
5. Funded by National funds through the FCT - Portuguese Science & Technology Foundation and co-funded by FEDER (Fundo Europeu de Desenvolvimento Regional) funds through the COMPETE 2020 - Operacional Programme for Competitiveness and Internationalisation (POCI). "Tackling cancer stem cells: a challenge and an opportunity to advance in anti-cancer therapy (CANCERSTEM)" WP3 – "CSC plasticity: EMT and stem cell state generation", (POCI-01-0145-FEDER-016390; 01/2017-12/2019). **2017-2019. BUDGET: € 85.640,00**
6. Funded by NORTE2020 and FEDER (Fundo Europeu de Desenvolvimento Regional) funds through the COMPETE 2020 - Operacional Programme for Competitiveness and Internationalisation (POCI) and Portugal 2020. "Diabetes & obesity at the crossroads between Oncological and Cardiovascular diseases – a system analysis NETtwork towards precision medicine (DOCnet)", (NORTE-01-0145-FEDER-000003). **2016-2018. BUDGET: € 122.352,00**
7. Funded by NORTE2020 and FEDER (Fundo Europeu de Desenvolvimento Regional) funds through the COMPETE 2020 - Operacional Programme for Competitiveness and Internationalisation (POCI) and Portugal 2020. "Tumour secreted factors in EMT/non-EMT cells for invasion and metastization", (NORTE-01-0145-FEDER-000029). **2016-2018. BUDGET: € 124.876,00**
8. Funded by NORTE2020 and FEDER (Fundo Europeu de Desenvolvimento Regional) funds through the COMPETE 2020 - Operacional Programme for Competitiveness and Internationalisation (POCI) and Portugal 2020. "Mapping genetic and phenotypic heterogeneity in HER2 positive cancers to anticipate and counteract resistance phenotypes", (NORTE-01-0145-FEDER-000029). **2016-2018. BUDGET: € 265.641,00**
9. Funded by IPATIMUP: "The intronic regulation of The CDH1 gene"; (2016-2018). **BUDGET: 25.000,00€**
10. Funded by IPATIMUP: "The role of Gastric Cancer cell-derived extracellular vesicles"; (2016-2018). **BUDGET: 25.000,00€**
11. Portuguese Science & Technology Foundation: "A 3D microarray platform for the high-throughput analysis of the role of the extracellular matrix in cancer-associated epithelial-to-mesenchymal transitions". (PTDC/BBB-ECT/2518/2014); (2016-2018); **(co-PI at Ipatimup). BUDGET: € 199.752,00€**
12. Funded by the American association "NSFC - No Stomach for Cancer": "Defining the Contribution of Mutations in CDH1 Non-Coding Regions and Other Known Susceptibility Genes to Hereditary Gastric Cancer"; Collaboration and Partnership with David Huntsman from the BCCA, Vancouver Canada and the International Gastric Cancer Linkage Consortium (IGCLC); (07/2014-06/2016). **BUDGET: USD 50.000**
13. Funded by Coimbra Genomics and BGI: "NGSGC - Using NGS to uncover structural and regulatory variation in gastric cancer"; (09/2013-11/2016). **BUDGET: 90.000,00€**
14. Funded by Portuguese Science & Technology Foundation: "TUMORTAG - Tumor-targeted nanoparticles for early diagnosis of gastric cancer"; (PTDC/CTM-NAN/120958/2010); (2012-2015); **(co-PI at Ipatimup). BUDGET: 153.895,00€**
15. Funded by Portuguese Science & Technology Foundation: "New E-cadherin RNAs: the dark side of a tumour suppressor gene"; (PTDC/SAU-GMG/110785/2009); (2011-2014). **BUDGET: 183.000,00€**

16. Funded by Calouste Gulbenkian Foundation: "Mutated suppressor tRNAs as a therapeutic tool for cancer associated syndromes: HDGC as a model"; (2009-2011). **BUDGET: 50.000,00€**
17. Funded by IPATIMUP: "MicroRNAs in gastric cancer"; (2009-2011). **BUDGET: 47.000,00€**
18. Funded by Portuguese Science & Technology Foundation: "Role of novel regulatory mechanisms in the loss of E-cadherin expression"; (PTDC/SAU-GMG/72168/2006); (2007-2010). **BUDGET: 150.000,00€**
19. Funded by Portuguese Science & Technology Foundation: "Identification of molecular mechanisms underlying gastric cancer in positive and negative families for germline CDH1 mutations"; (POCI/SAU-OBS/58111/2004); (2005-2008). **BUDGET: 92.180,00€**

TEAM MEMBER (n=16 projects with a total budget of 2.5M€)

1. Portuguese Science & Technology Foundation: "MISTiC- MIStranslation: a novel trigger of genome instability In Cancer". Project number 28.834; (2018-2021).
2. Portuguese Science & Technology Foundation: "Improving gastric cancer patient stratification towards personalised therapy". iFCT to Gabriela M Almeida; (2014-2018).
3. Portuguese Science & Technology Foundation: "Understanding the impact of acquired and germline genetic variants in the complexity of gastric cancer." iFCT to Pedro G Ferreira; (2015-2020).
4. Portuguese Agency of Research and Innovation: "Musa - Detecção de mutações em sangue periférico". Project number 38704; (2013-2015).
5. Funded from the European Union Seventh Framework Programme [FP7-PEOPLE-2012-ITN]. Grant agreement n° [316975]. Research Group from Partner Organization hosting secondments from the project "The Singlet Oxygen Strategy (SO2S)".
6. Portuguese Science & Technology Foundation: "Adhesion, Differentiation and Invasion: different processes, common cadherin players"; (PTDC/SAU-GMG/120049/2010); (2012-2015)
7. Portuguese Science & Technology Foundation: "Tumour spectrum in hereditary Diffuse Gastric Cancer"; (PTDC/SAU-ONC/110294/2009); (2011-2014)
8. Portuguese Science & Technology Foundation: "Functional genomics of ribosome infidelity phenotypes associated to human diseases"; (PTDC/SAU-GMG/098850/2008); (2010-2013)
9. Portuguese Science & Technology Foundation: "Exploring the role of E-Cadherin-HER interaction in the search of molecular biomarkers for the clinical management of gastric cancer patients"; (PIC/IC/82923/2007); (2009-2012)
10. Portuguese Science & Technology Foundation: "Implementation of a National Facility for DNA Microarrays: Phase II"; (PTDC/BIA-BCM/64745/2006); (2009-2011)
11. Portuguese Science & Technology Foundation: "MLK3, a new mutated gene in MSI colorectal cancer"; (PTDC/SAU-OBD/68310/2006); (2008-2011)
12. FP6, Program for research and technological development for specific targeted research project "Prevention, detection and molecular characterization of mismatch repair-related hereditary cancers of the digestive system"; (Contract LSCH-CT-2005-018754, MMR-related cancer); (2006-2009)
13. Portuguese Science & Technology Foundation: "Identification of signaling pathways involved in Cdx2 regulation in two human models of altered intestinal differentiation: intestinal metaplasia and juvenile polyposis"; (POCI/SAU-OBS/55840/2004); (2005-2008)
14. Portuguese Science & Technology Foundation: "In mismatch repair deficiency colorectal cancer are BRAF and KRAS new prognostic and therapeutic tools?"; (POCI/SAU-OBS/56921/2004); (2005-2008)
15. Portuguese Agency of Research and Innovation: "Mechanisms interfering with cellular invasion and applications in oncology and pre-natal diagnosis"; (INV-ONC-DPN); (2005-2007)
16. Portuguese Science & Technology Foundation: "E-cadherin germline mutations and hereditary diffuse gastric cancer: functional, biochemical and molecular characterization"; (POCTI/CBO/40820/2001); (2002-2005)

Funding for Personnel

Overall budget obtained for personnel so far = €1.500.000 (based on Portuguese salary/fellowship scale)
In total, Carla Oliveira's team has been successful in the application for **26 PhD, Post-doc or iFCT** proposals.

- BiotechHealth PhD Program/FCT; One PhD Fellowship; (2016-2019)
- Portuguese Science & Technology Foundation; One PhD Fellowship; (2016-2019)

- Portuguese Science & Technology Foundation; One Investigator FCT contract; (2015-2019)
- Portuguese Science & Technology Foundation; One Investigator FCT contract; (2014-2018)
- BiotechHealth PhD Program/FCT; One PhD Fellowship; (2014-2017)
- Portuguese Science & Technology Foundation; Two PhD Fellowships; (2013-2016)
- Portuguese Science & Technology Foundation; Three Post-doc Fellowships; (2013-2015)
- Portuguese Science & Technology Foundation; One Sabbatical Fellowship to Carla Oliveira; (2011-2012)
- Portuguese Science & Technology Foundation; Three Post-doc scholarships; (2012-2015)
- Portuguese Science & Technology Foundation; Two Ph.D. scholarships; (2009-2012)
- Portuguese Science & Technology Foundation; One Ciência 2007 contract; (2008-2012)
- Portuguese Science & Technology Foundation; Two Ph.D. scholarships; (2008-2011)
- EMBO short term fellowships; Four fellowships for Ph.D. students; (2008-2011)
- Portuguese Science & Technology Foundation; Two Ph.D. scholarships; (2005-2008)
- EACR travel fellowship European Association for Cancer Research (EACR); €2.000,00 (2005)

Supervision Experience

PAST Supervision *of Students and Post-Doctoral fellows:*

POST-DOCTORAL SUPERVISION

1. Hugo Pinheiro "CDH1 EXPRESSION REGULATION: AN ALTERNATIVE MOLECULAR CAUSE FOR HEREDITARY DIFFUSE GASTRIC CANCER" (Ref.SFRH/BPD/79499/2011 - 2nd Trienium). Currently a Medical doctor completing the General Internship and a Consultant in my group at PATIMUP/i3S, Porto, Portugal

2. Hugo Pinheiro "CDH1 LOCUS, THE NEXT JEKYLL AND HYDE IN CANCER?" (Ref.SFRH/BPD/79499/2011 1st Trienium).

3. Patricia Oliveira "ALL TOGETHER NOW: COMBINED INFLUENCE OF E-CADHERIN MODULATORS IN EPITHELIAL- MESENCHYMAL-EPITHELIAL TRANSITIONS AND CANCER PROGRESSION" (Ref. SFRH/BPD/89764/2012 – 1st Trienium). Currently doing the 2nd Postdoc triennium in my group at PATIMUP/i3S, Porto, Portugal

4. Joana Carvalho "STUDY OF SECRETED CELL VESICLES DURING EPITHELIAL-MESENCHYMAL-EPITHELIAL TRANSITIONS AND THEIR ROLE IN THE CANCER METASTATIC PROCESS" (Ref. SFRH/BPD/86543/2012 – 1st Trienium). Currently doing the 2nd Postdoc triennium in my group at PATIMUP/i3S, Porto, Portugal

5. Ana Sofia Ribeiro "ADHESION, DIFFERENTIATION AND INVASION: DIFFERENT PROCESSES, COMMON CADHERIN PLAYERS". (Ref. PTDC/SAU-GMG/120049/2010). (Co-supervision). Currently a Postdoc with Joana Paredes, IPATIMUP/i3S, Porto Portugal

6. Gabriela Almeida "TARGETING CHEMOTHERAPY-INDUCED EMT AND CANCER STEM CELLS FOR OVERCOMING TUMOUR DRUG RESISTANCE" (Ref. SFRH/BPD/87257/2012). Post-doc ended on the 31.12.2013. Funded with an iFCT contract as Auxiliary Investigator for 5 years from the Portuguese Foundation for Science and Technology to work in my group at IPATIMUP/i3S, Porto, Portugal

7. Patricia Pereira in the frame of the project "FUNCTIONAL GENOMICS OF RIBOSOME INFIDELITY PHENOTYPES ASSOCIATED TO HUMAN DISEASES". Post-doc ended on the 31.12.2012. Currently a Medical doctor completing the specialization

8. Denisa Mateus in the frame of the project "NEW E-CADHERIN RNAS: THE DARK SIDE OF A TUMOUR SUPPRESSOR GENE". Post-doc ended on the 16.02.2013. Currently a Post-doc at the Centre of Neurosciences, Coimbra, Portugal

Ph.D. SUPERVISION

1. Mafalda Santos "UNRAVELLING THE ROLES OF STATISTICAL PROTEOMES IN HUMAN CANCER" (Ref: SFRH/BD/91020/2012). **Graduated in February 2018** (Co-supervision). Currently a Post-doc at the iBiMED, Univ. Aveiro, Porto, Portugal

2. Ana Sofia Varanda "UNRAVELLING THE CELLULAR NETWORKS THAT REGULATE PROTEOTOXIC STRESS" (SFRH/BD/76417/2011). **Graduated in March 2017** (Co-supervision). Currently a Post-doc at the iBiMED, Univ. Aveiro, Porto, Portugal

3. Renata Bordeira-Carriço on "SUPPRESSOR-TRNAS AS THERAPEUTIC TOOLS FOR CANCER ASSOCIATED SYNDROMES: HDGC AS A MODEL SYSTEM", FMUP, Univ. Porto, Portugal. **Graduated in March 2013**. Currently a Post-doc at the IBMC/i3S, Porto, Portugal

4. Joana Carvalho on "THE INVOLVEMENT OF MICRORNAS IN GASTRIC CANCER", FMUP, Univ. Porto, Portugal. **Graduated in December 2012**. Currently a FCT-funded Post-doc in my group at IPATIMUP/i3S, Porto, Portugal

5. Patricia Oliveira "IDENTIFICATION OF NOVEL CIS-REGULATORY ELEMENTS IN THE CADHERIN SUPERFAMILY AND CHARACTERIZATION OF THEIR ROLE IN CANCER-RELATED PROCESSES", ICBAS, Univ. Porto, Portugal. **Graduated in February 2012**. Currently a FCT-funded Post-doc in my group at IPATIMUP/i3S, Porto, Portugal

6. Hugo Pinheiro "E-CADHERIN: NEW REGULATORY MECHANISMS IN CANCER", FMUP, Univ. Porto, Portugal. **Graduated in December 2011**. Currently a FCT-funded Post-doc in my group at IPATIMUP/i3S, Porto, Portugal

7. Sérgia Velho "THE ROLE OF BRAF AND KRAS ACTIVATING MUTATIONS IN DEFICIENT AND PROFICIENT MMR COLORECTAL CARCINOMAS", FMUP, Univ. Porto, Portugal. **Graduated in May 2010** (Co-supervision). Funded with an iFCT contract for 5 years from the Portuguese Foundation for Science and Technology

8. Sónia Melo "EPIGENETIC, GENETIC AND FUNCTIONAL ANALYSES OF MICRORNA-MACHINERY IN HUMAN CANCER", FMUP, Univ. Porto, Portugal. **Graduated in May 2010** (Co-supervision). Currently Human Frontiers Postdoctoral Fellow at MD Anderson Cancer Center, USA. Funded with a iFCT from the Portuguese Foundation for Science and Technology

9. Rachid Karam "THE ROLE OF NONSENSE-MEDIATED MRNA DECAY (NMD) IN THE REGULATION OF CDH1 GENE EXPRESSION AND CANCER DEVELOPMENT", FMUP, Univ. Porto, Portugal. **Graduated in December 2008**. Currently an Oncogenetics Specialist at Ambry Genetics San Diego, California, USA

MASTERS THESIS SUPERVISION

1. Celina Beatriz Teixeira São José "THE GERMLINE AND SOMATIC LANDSCAPE OF FAMILIAL INTESTINAL GASTRIC CANCER: SEARCH FOR A CAUSE". Master in Oncology, ICBAS, Univ. Porto, Portugal. **Graduated in November 2017**

2. Ana Sofia Valente "CDH1 REGULATORY VARIANTS AND HEREDITARY DIFFUSE GASTRIC CANCER". Univ. Porto, Portugal. Masters in Molecular and Cellular Biology, FCUP, Univ. Porto, Portugal. **Graduated in November 2016.**

3. Ana Aguiar "CHARACTERIZATION OF AN E-CADHERIN-RELATED COMMON ANCESTOR IN HEREDITARY DIFFUSE GASTRIC CANCER FAMILIES FROM THE NORTHERN PORTUGAL". Integrated Masters in Medicine, FMUP, Univ. Porto, Portugal. **Graduated in July 2016**. Currently doing an internship as a Medical Doctor

4. Hugo Pinheiro "HEREDITARY DIFFUSE GASTRIC CANCER BEYOND *CDH1* CODING MUTATIONS". Univ. Minho, Braga, Portugal. Integrated Masters in Medicine, Univ. Minho, Portugal. **Graduated in January 2016**.

5. Pedro Queirós "KRAS MUTATIONS IN MICROSATELLITE INSTABLE GASTRIC TUMOURS: IMPACT OF TARGETED TREATMENT AND INTRATUMOURAL HETEROGENEITY". Integrated Masters in Medicine FMUP, Univ. Porto, Portugal. **Graduated in June 2015**. Currently a Medical Doctor

6. Inês Reis "DIES1 GENE EXPRESSION AND REGULATION IN GASTRIC CANCER". ICBAS, Univ. Porto, Portugal. **Graduated in November 2014**. Currently Technician at the Hospital Geral Santo António, Porto Portugal

7. Mafalda Azevedo "AN IN VITRO MODEL OF EMT/MET USING HUMAN NEAR-NORMAL AND CANCER-DERIVED BREAST CELL LINES". ICBAS, Univ. Porto, Portugal. **Graduated in December 2012**. Currently a GABBA PhD Program student, New York, USA

8. Pedro Freitas, "EXPRESSION ANALYSIS OF MICRORNAS TARGETING ADHESION COMPLEX MOLECULES IN GASTRIC CANCER". Integrated Masters in Medicine, FMUP, Univ. Porto, Portugal. **Graduated in June 2012**. Currently a Medical Doctor

9. Hugo Pinheiro "E-CADHERIN SILENCING: MORE THAN INACTIVATING MUTATIONS". Univ. Minho, Braga, Portugal. **Graduated in 2007**

***CURRENT Supervision** of Students and Post-Doctoral fellows:*

POST-DOCTORAL SUPERVISION

1. Patricia Oliveira "EMT/MET IN GASTRIC CANCER: USING NEXT GENERATION SEQUENCING DATA TO UNCOVER NOVEL THERAPEUTIC TARGETS" (Ref. SFRH/BPD/89764/2012 – 2nd Trienium)

2. Joana Carvalho "CIRCULATING EXOSOMES: A TOOL TO FOLLOW GASTRIC TUMOUR DYNAMICS AND THERAPY RESPONSE" (Ref. SFRH/BPD/86543/2012 – 2nd Trienium)

3. Silvia Bidarra "ARTIFICIAL EXTRACELLULAR MATRIX-LIKE MATRICES AS 3D IN VITRO MODELS TO INVESTIGATE THE ROLE OF THE MICROENVIRONMENT IN CANCER METASTISATION" (Ref. SFRH/BPD/80571/2011 – 2nd Trienium). Collaboration with Cristina Barrias, INEB, Porto Portugal (Co-supervision)

4. Tiago Santos "TISSUE ENGINEERED 3D MODELS OF GASTRIC WALL FOR PERMEABILITY STUDIES OF DRUGLOADED NANOPARTICLES" (SFRH/BPD/103113/2014). Collaboration with Pedro Granja and Bruno Sarmento, INEB, Univ. Porto, Porto Portugal (Co-supervision)

Ph.D. THESIS SUPERVISION

1. Rúben Rodrigues "DEVELOPMENT OF AN INTEGRATED KNOWLEDGE BASE FOR GASTRIC CANCER" (FCT Ref: SFRH/BD/131916/2017). (Co-supervision). Collaboration with Miguel Rocha, University of Minho, Braga, Portugal

2. Abel Sousa "STUDY OF CONTROL OF PROTEIN ABUNDANCE USING MULTI-OMICS DATA FROM CANCER SAMPLES" (GABBA Program Ref: PD/BD/128007/2016).

3. Sara Rocha "DECONSTRUCTING GASTRIC CANCER COLONIZATION: THE INTERPLAY BETWEEN IMMUNE CELLS, GASTRIC CANCER CELLS AND EXTRACELLULAR VESICLES" (BiotechHealth PhD Program/FCT PD/BD/128406/2017)

4. Carla Pereira "UNVEILING THE CROSSTALK BETWEEN E-CADHERIN AND CD44-SPLICE VARIANTS AS A NOVEL STRATEGY TO IMPROVE DRUG SENSITIVITY IN GASTRIC CANCER" (SFRH/BD/113031/2015)

5. Bianca Lourenço "FUNCTIONALIZED NANOPARTICLES AS SCREENING METHODOLOGY FOR EARLY DIAGNOSIS OF INVASIVE GASTRIC CANCER" (Ref: SFRH/BD/87400/2012). (Co-supervision). Collaboration with Pedro Granja, INEB, Univ. Porto, Porto Portugal

6. Patrick Kennedy "INNOVATIVE COLORECTAL CANCER DIAGNOSIS AND TREATMENT WITH ENGINEERED NANOPARTICLES" (SFRH/BD/99036/2013). (Co-supervision). Collaboration with Bruno Sarmento and Pedro Granja, INEB, Univ. Porto, Porto Portugal

7. Daniel Ferreira "A TISSUE ENGINEERING APPROACH TO BUILDING A STOMACH-ON-A-CHIP" (PD/BD/105976/2014). (Co-supervision). Collaboration with Pedro Granja, INEB, Univ. Porto, Porto Portugal

8. Irene Gullo "MORPHOLOGICAL AND IMMUNOPHENOTYPIC HETEROGENEITY IN GASTRIC CANCER". (2013-2016). (Co-supervision). Collaboration with Fátima Carneiro, FMUP, Univ. Porto, Porto Portugal

MASTERS THESIS SUPERVISION

1. Sara Teles "DISCLOSING HYPOMETHYLATION AS AN ONCOGENE ACTIVATION MECHANISM". Master in Oncology, ICBAS, Univ. Porto, Portugal. 2016/2018

2. Ana Rita Matos "CDH1 GENOMIC BLUEPRINT: THE ROLE OF ITS CIS-REGULATORY ELEMENTS". Master in Medical and Molecular Oncology, FMUP, Univ. Porto, Porto Portugal

Summary of Under-graduate Students PAST Supervision

1. Degree Training supervision of Sara Teles, Univ. Porto, Portugal. Graduated in 2016
2. Degree Training supervision of Mafalda Azevedo, Univ. Aveiro, Portugal. Graduated in 2011
3. Degree Training supervision of Catarina Salgado, Univ. Porto, Portugal. Graduated in 2010
4. Degree Training supervision of Patrícia Inácio, Univ. Porto, Portugal. Graduated in 2007
5. Degree Training supervision of Sónia Melo, Univ. Porto, Portugal. Graduated in 2005
6. Degree Training Supervision of Sérgia Velho, Univ. Porto, Portugal. Graduated in 2004

Carla Oliveira has been involved since 2000 in teaching activities in Oncobiology for students from:

1. GABBA PhD program, Porto University, Portugal
2. Other Porto University Doctoral programs, Porto, Portugal
3. Gulbenkian PhD programs, Lisbon, Portugal
4. Medical Sciences Faculty - NOVA University Doctoral program, Lisbon
5. Masters Program in Molecular Medicine, Medical Faculty, Porto University, Portugal
6. Masters Program in Oncobiology, Medical Faculty, Porto University, Portugal
7. FMUC PhD Program in Health Sciences, Coimbra University, Portugal

Thesis committees and Jury (Examiner = 22; Jury member = 26)

1. Invited Jury member (**examiner**): Ph.D. Thesis of Joana Lima. Univ. Porto, Portugal; 2018
2. Invited Jury member (**examiner**): Masters Dissertation of Ricardo Cunha. Univ. Porto, Portugal; 2017
3. Member of the Masters Dissertation Committee of Celina São José. Univ. Porto, Portugal; 2017
4. Invited Jury member (**examiner**): Ph.D. Dissertation of Ana Metelo. Univ. Coimbra, Portugal; 2017
5. Invited Jury member (Pre-**examiner**): Ph.D. Thesis of Elisa Lazaro Ibanez. Univ. Helsinki; 2017
6. Member of the Ph.D. Dissertation Committee of Ana Sofia Varanda. Univ. Aveiro, Portugal; 2017
7. Member of the Masters Dissertation Committee of Ana Aguiar. Univ. Porto, Portugal; 2016
8. Invited Jury member (**examiner**): Ph.D. Dissertation of Suellen Ferro. Univ. Porto, Portugal; 2016
9. Invited Jury member (**examiner**): Masters Dissertation of Diana Pinto. Univ. Porto, Portugal; 2015
10. Invited Jury member (**examiner**): Masters Dissertation of Rita Faria. Univ. Porto, Portugal; 2015
11. Member of the Ph.D. Dissertation Committee of Bruno Albuquerque. Univ. Porto, Portugal; 2015
12. Member of the Ph.D. Dissertation Committee of João Curado e Silva. Univ. Porto, Portugal; 2015
13. Member of the Ph.D. Dissertation Committee of Joana Santos. Univ. Porto, Portugal; 2015
14. Member of the Masters Dissertation Committee of Pedro Queirós. Univ. Porto, Portugal; 2015
15. Member of the Ph.D. Dissertation Committee of Margherita Francescatto. Univ. Porto, Portugal; 2015
16. Member of the Ph.D. Dissertation Committee of Germana Domingues. Univ. Lisbon, Portugal; 2014

17. Invited Jury member (**examiner**): Ph.D. Dissertation of Joana Costa. Univ. Lisbon, Portugal; 2014
18. Member of the Ph.D. Dissertation Committee of Irina Amorim. Univ. Porto, Portugal; 2014
19. Invited Jury member (**examiner**): Masters Dissertation of João Coentro. Univ. Porto, Portugal; 2014
20. Member of the Masters Dissertation Committee of Inês Reis. Univ. Porto, Portugal; 2014
21. Invited Jury member (**examiner**): Masters Dissertation of Rui Barranha. Univ. Porto, Portugal; 2014
22. Invited Jury member (**examiner**): Ph.D. Dissertation of Ana Ramos. Univ. Coimbra, Portugal; 2014
23. Member of the Ph.D. Dissertation Committee of Bruno Pereira. Univ. Porto, Portugal; 2013
24. Invited Jury member (**examiner**): Ph.D. Dissertation of Pedro Costa. Univ. Coimbra, Portugal; 2013
25. Member of the Ph.D. Dissertation Committee of Renata Bordeira-Carriço. Univ. Porto, Portugal; 2013
26. Invited Jury member (**examiner**): Ph.D. Dissertation of Cristovão Sousa. L'Université Pierre et Marie Curie. Paris, France; 2013
27. Member of the Ph.D. Dissertation Committee of Joana Carvalho. Univ. Porto, Portugal; 2012
28. Invited Jury member (**examiner**): Masters Dissertation of Diana Sobral Mesquita. Univ. Porto, Portugal; 2012
29. Member of the Masters Dissertation Committee of Mafalda Azevedo. Univ. Porto, Portugal; 2012
30. Invited Jury member (**examiner**): Ph.D. Dissertation of Inês Almeida. ICVS - Universidade do Minho. Braga, Portugal; 2012
31. Invited Jury member (**examiner**): Ph.D. Dissertation of Fatiha Sangar. L'Université Pierre et Marie Curie. Paris, France; 2012
32. Member of the Ph.D. Dissertation Committee of Giovanni Corso. Univ. Porto, Portugal; 2012
33. Invited Jury member (**examiner**): Ph.D. Dissertation of Joana Domingues. Univ. Porto, Portugal; 2012
34. Invited Jury member (**examiner**): Ph.D. Dissertation of Bruno Cardoso. Univ. Lisbon, Portugal; 2011
35. Member of the Ph.D. Dissertation Committee of Hugo Pinheiro. Univ. Porto, Portugal; 2011
36. Member of the Ph.D. Dissertation Committee of Joana Fernandes. Univ. Porto, Portugal; 2011
37. Member of the Ph.D. Dissertation Committee of Denisa Mateus. Univ. Aveiro, Portugal; 2011
38. Invited Jury member (**examiner**): Masters Dissertation of Rita Domingues. Univ. Porto, Portugal; 2010
39. Member of the Ph.D. Dissertation Committee of Sérgia Velho. Univ. Porto, Portugal; 2010
40. Member of the Ph.D. Dissertation Committee of Sónia Melo. Univ. Porto, Portugal; 2010
41. Invited Jury member (**examiner**): Masters Dissertation of Filipa Sousa. Univ. Porto, Portugal; 2009
42. Member of the Ph.D. Dissertation Committee of Joana Simões-Correia. Univ. Porto, Portugal; 2009
43. Member of the Ph.D. Dissertation Committee of Ana Rita Mateus. Univ. Porto, Portugal; 2009
44. Invited Jury member (**examiner**): Ph.D. Dissertation of Ana Paula Elias. Univ. Lisbon, Portugal; 2008
45. Member of the Ph.D. Dissertation Committee of Rachid Karam. Univ. Porto, Portugal; 2008
46. Invited Jury member (**examiner**): Masters Dissertation of Renata Carriço. Univ. Lisbon, Portugal; 2007
47. Member of the Ph.D. Dissertation Committee of Catarina Castro Alves. Univ. Porto, Portugal; 2007

Reviewing duties

1. ***Peer Review Journals***: Journal of Pathology; Oncogene; BMC Cancer; Annals of Human Genetics; European Journal of Human Genetics; Cellular Oncology; Familial Cancer; Future Oncology; Clinical Genetics; European Journal of Cancer; International Journal of Cancer; Carcinogenesis; Virchows Archives; World journal of Gastroenterology; Epigenomics; PlosOne; BMC Genomics; Human Molecular Genetics; Genome Research; Lancet Oncology; Gastroenterology; Frontiers in Genetics

2. ***Funding agencies***: Health Research Council of New Zealand; ICS-Institut Clinique de la Souris, France; Dutch Cancer Society (KWF Kankerbestrijding); Portuguese Foundation of Science and Technology (FCT): Research Projects, PhD and Post-doc grant applications (http://www.fct.pt/apoios/bolsas/concursos/membros?idc=28&idav=38&idp={8AB5E1CF-5699-4213-966A-C2E899921CB0}&show=elems)

Oral Communications – National and International – by invitation (n=80)

1. "Redefining Germline Mechanisms of Disease". Lecture on GABBA Oncobiology Module, Porto, Portugal, March 2018

2. "Horizontally transferable mechanisms in gastric cancer: modulators of cellular behaviour and cancer biomarkers". 1st Meeting on Vesicular Biology, Coimbra, Portugal, February 2018
3. "Genes supressores tumorais e instabilidade genética". Lecture on PDMOM/MOM PhD program – Oncobiology course – IPATIMUP, Portugal, January 2018
4. "From diseases to causative molecular events: genetic, epigenetic and horizontally transferable mechanisms". Lecture on Molecular Mechanisms of Disease, PhD Program in Health Sciences, FMUC, December 2017
5. "Light and Antibodies Fighting Gastric Cancer". I3S Distinguished Lectures. I3S Annual Meeting 2017, Póvoa de Varzim, Portugal, November 2017
6. "Genetics and gastric cancer". Session: Which diseases are inherited? UEG United European Gastroenterology Week 2017, Barcelona, October 2017
7. "Hereditary gastric cancer". Lecture on post-graduate course - A Multidisciplinary approach to Hereditary GI Cancers: from Bench to Bedside (ESDO-ESGE-InSIGHT), Florence, Italy, July 2017
8. "CDH1 germline noncoding defects: the missing mechanisms in Hereditary Diffuse Gastric Cancer". One Day Symposium with Patrick Tan: Knowns & Unknowns in Gastric Cancer and Other Tumours of the Digestive System, i3S, Porto, Portugal, June 2017
9. "Clinical utility of high-throughput genome analysis and impact for patient treatment". First DOCnet Consortium Meeting, Faculty of Medicine of the University of Porto (FMUP), Portugal, May 2017
10. "microRNAs in screening programs of high risk patients/regions: how far are we?". Esophagus and Gastric Cancer Session. Leaping Forward Oncology – International Clinical Congress 2017, Lisbon, May, 2017
11. "Tumor cell invasion and metastasis: Epithelial to mesenchymal transition and cancer cell plasticity". VII Workshop on Cancer Research, IPATIMUP Porto, Portugal, May 2017
12. "Current challenges in familial gastric cancer". Lecture on Master course - Oncobiologia da Faculdade de Medicina de Lisboa (FMUL) – Módulo de Risco Familiar. Lisbon, Portugal, May, 2017
13. "Oncogenes and Tumor suppressor genes". Invited lecture at ICBAS, Portugal, May, 2017
14. "The translational value of germline and somatic mechanisms for diagnosis and anti-cancer therapy in gastric cancer". Integrative Program Seminar Series: Cancer Research Line, i3S, Porto, Portugal, April 2017
15. "Molecular determinants of gastric cancer: genotypes, phenotypes and impact in progression and treatment". Seminar at Instituto de Saúde Pública da Universidade do Porto (ISPUP), Porto, Portugal March, 2017
16. "Redefining germline mechanisms of disease". Lecture on GABBA Oncobiology Module, Porto, Portugal, February 2017
17. "Genes supressores tumorais e instabilidade genética". Lecture on PDMOM/MOM PhD program – Oncobiology course – IPATIMUP, Portugal, January 2017
18. "From disease to causative gene events: an omics approach in gastric cancer". Keynote Lecture XIX National Congress of Biochemistry, Guimarães, Portugal, December 2016
19. "Current challenges in familial gastric cancer". Symposium update – erbliche gastrointestinale karzinomerkrankungen Munich, Germany November 2016
20. "Molecular determinants of gastric cancer: genotypes, phenotypes and impact in progression and treatment". Seminar series National Cancer Center Research Institute, Tokyo, Japan, August 2016
21. "Cancro gástrico esporádico e familiar: aspectos genéticos". I Congresso da EUROPACOLON Portugal em Oncologia Digestiva. Fundação Cupertino Miranda, Porto, Portugal, July 2016
22. "From single genes to full genomes, from single mechanisms to complex pathways". iBiMED International Advanced Training School. Omics in Biomedicine: linking genes and metabolites, iBiMED Aveiro, Portugal, June 2016
23. "Tumor cell invasion and metastasis: Epithelial to mesenchymal transition and cancer cell plasticity". VI Workshop on Cancer Research, IPATIMUP Porto, Portugal, May 2016

24. "Epigenetic mechanisms of gene expression regulation in gastric cancer". ICVS Course Epigenetics - from mechanisms to disease. Braga, Portugal. April 2016

25. "From single causing genetic mutations to multiple modifying mutations in cancer- the journey of a life-time". III Jornadas da Bioquímica "Bioquímicos pelo Mundo". Porto, Portugal. April 2016

26. "Hereditary Diffuse Gastric Cancer". 1st Spring Course in Hereditary Cancer Genetics. Bertinoro, Italy. April 2016

27. "Effect of cancer cell-derived extracellular vesicles over normal cells from the microenvironment". Spring Meeting of the Cost Action European Network on Microvesicles and Exosomes in Health and Disease, Ioannina, Greece, March 2016

28. "Molecular determinants of cancer: genotypes and phenotypes". iBiMED Seminar Series. Aveiro, Portugal. October 2015

29. "From single causing genetic mutations to multiple modifying mutations in cancer". INEB Summer Science Club: Integrating Competences. Porto, Portugal. July 2015

30. "GASTRIC CANCER THERAPY, THE ERA OF FUNCTIONAL GENOMICS". Post-graduated course "Cancer therapy: from basic reasearch to clinic", Dept of Biology, University of Minho, Braga, Portugal, June 2015

31. "Genomics and Transcriptomics in cancer research". V Workshop on Cancer Research – Biological and molecular basis. IPATIMUP/ICBAS, Porto, Portugal, May 2015

32. "Genómica e Bioinformática: O que o clínico deve saber". XXXVI Congresso Português de Cardiologia. Albufeira, Portugal, April 2015

33. "The genomics and bioinformatics era: does it help understanding better sporadic and hereditary cancer?" Research Seminar, IPO, Instituto Português de Oncologia, Lisbon, Portugal, February 2015

34. "Using NGS to uncover structural and regulatory variation in gastric cancer" COIMBRA GENOMICS Annual MEETING, CURIA, Portugal, January 2015

35. "Germline and somatic determinants of gastric cancer: Next Generation Sequencing and Functional Genomics". Ministry of Health - MD Anderson Cancer Center Joint Conference on Gastric and Hereditary Cancer, Lisbon Academic Medical Center Lisbon, Portugal, November 2014

36. "Through the looking glass: the reversion of EMT". 1st International Congress ASPIC – Associação Portuguesa de Investigação em cancro. Lisbon, Portugal, November 2014

37. "Hereditary GI cancer: New genes, old diseases". UEG – United European Gastroenterology Week, Vienna Austria October 2014

38. "The role and cargo of EVs in epithelial-mesenchymal-epithelial transitions and gastric cancer progression". II GEIVEX SYMPOSIUM: Extracellular vesicles, from the bench to the clinics. Satellite Meeting of the Portuguese Groups on Extracellular Vesicles, Taragona, Spain, October 2014

39. "The role and cargo of EVs in epithelial-mesenchymal-epithelial transitions and gastric cancer progression". Autumn Meeting of the Cost action European Network on Microvesicles and Exosomes in Health and Disease, Palermo, Italy, September 2014

40. "Can you use next generation sequencing data from tumours to rationally select targeted therapy approaches?". BioP5med Unworkshop, IGC - Oeiras, Lisbon, Portugal, July 2014

41. "Metastable phenotypes". ONCOBIOLOGY - genes and tumoral microenviroment Seminar Series. Medical Sciences Faculty - NOVA University, Lisbon Portugal May 2014

42. "Germline and somatic determinants in gastric cancer: a focus on E-cadherin". ONCOBIOLOGY - genes and tumoral microenviroment Seminar Series. Medical Sciences Faculty - NOVA University, Lisbon Portugal May 2014

43. "Genomics and Transcriptomics in cancer research". 4rd Workshop on Cancer Research, IPATIMUP Porto, Portugal, May 2014

44. "Next Generation Sequencing (NGS): Principles and clinical aplications". 6th Scientific Meeting of the Portuguese Society of Clinical Chemistry and Laboratorial Medicine, Coimbra, Portugal, April 2014

45. "Germline and somatic determinants in gastric cancer: a focus on E-cadherin". Oncology Meetings: Gastric Cancer - State of Art. University of Minho, Braga, Porto, Portugal, March 2014

46. "Using NGS and in Vitro Models to Understand Structural and Regulatory Variation in Gastric Cancer" Bio-IT World and Cambridge Healthtech Institute's Second Annual, Clinical Genomics and Genome Informatics Europe, Deciphering Disease through Sequencing Data, Lisbon Portugal, December 2013

47. "Using molecular stratification and NGS to Understand Structural and Regulatory Variation in Gastric Cancer" 17th SPGH Annual Meeting, Coimbra Portugal, November 2013

48. "Modulation of cell-cell adhesion in cancer and epithelial-mesenchymal-epithelial transition?" IMM Monday lectures, IMM Lisbon Portugal, November 2013

49. "Metastastic pathways in gastric cancer: is there a role of Extracellular Vesicles?" 2nd Meeting COST Action_BM1202 ME-HAD, Semmelweis University NET building Budapest Hungary, October 2013

50. "Gerspermmline and somatic determinants in gastric cancer - impact in diagnosis, prognosis and treatment". Monday Seminar Medical Faculty University of Porto, Porto Portugal, October 2013

51. "Modulation of E-cadherin expression and function in gastric cancer - clinical and molecular features". 19TH GI CANCER FORUM - The Martin Cohen Lecture Theatre, CRUK CRI - Li Ka Shing Centre, Cambridge UK, September 2013

52. "Molecular mechanisms modulating the function of the invasion suppressor protein E-cadherin". Institut Curie, Université Paris-SUD, Paris, France, July 2013.

53. "HDGC: Updated guidelines for clinical management" IGCC 2013, 10th International Gastric Cancer Congress, Verona Italy, June 2013

54. "Cancer Metastization: *Examples from the wet lab".* 3rd Workshop on Cancer Research, IPATIMUP Porto Portugal May 2013

55. "Genetics of hereditary diffuse gastric cancer – HDGC". Funderburg Symposium - "Current Approach to Hereditary Diffuse Gastric Cancer (HDGC) syndrome". DDW 2013 Digestive Disease Week Orlando, USA, May 2013

56. "From disease to mechanisms: old and new stories about E-cadherin". IMMS - Instituto Mexicano de Seguro Social Guadalajara Mexico, January 2013

57. "Dissecting the role of cadherins with OMICS technologies". Course: "New frontiers of OMICs in Medicine - from the lab to a clinical setting". IBILI Coimbra, January 2013

58. "Dissecting the role of cadherins with genome-wide technologies". User Meeting Genómica. IBILI Coimbra, September 2012

59. "Novel molecular mechanisms modulating the function of the invasion suppressor protein E-cadherin". 2nd IBEC-INEB Advanced Summer School. IBEC Barcelona, June 2012

60. "From disease to mechanisms: old and new stories about E-cadherin". CDR Saint-Antoine. Paris France, April 2012

61. "Epigenetic Changes in Cancer and Epithelial to Mesenchymal Transitions". Mini-symposium on Epigenetics and Cancer. IBMC Porto, Portugal, March 2012

62. "E-cadherin the sticky component of epithelial tissues: old gene new stories". CEDOC. Lisbon, Portugal, May 2011

63. "Tumor cell invasion and metastasis. I Workshop on Cancer Research: biological and molecular basis. Porto, Portugal, May 2011

64. "Regulation of E-cadherin expression and function in cancer". BIOCANT, Coimbra, Portugal, May 2011

65. "Regulatory RNA molecules modulating the function of E-cadherin". Mini-Symposium on "Mechanisms of Gene Expression. IPATIMUP. Porto, Portugal, September 2010

66. "Functions of non-coding RNAs in gene regulation and disease". ICBAS. Porto, April 2010

67. "Coding and non-coding RNAs controlling E-cadherin expression and function". "RNA world: not so small" Life Technologies/Applied Biosystems Symposium. Porto, April 2010

68. "E-cadherin and Hereditary Diffuse Gastric Cancer (HDGC)". I Meeting on Biomedical Sciences. Aveiro, Portugal, March 2010

69. "Functions of non-coding RNAs in gene regulation and disease". Annual Meeting Portuguese Society of Human Genetics. Porto, Portugal, November 2009

70. "Nanoparticles as a vehicle to decrease cancer risk". Symposium 20 years of Biomagical Engineering. Tibães-Braga, Portugal, June 2009

71. "E-cadherin expression regulation in Cancer: new targets of regulation in the E-cadherin locus". SINAL 2009 - 3rd Meeting on Signal Transduction. Aveiro, Portugal, May 2009

72. "Modulating the expression of E-cadherin (CDH1) in Hereditary Diffuse Gastric Cancer. IGC. Lisbon, Portugal, December 2008

73. "Modulating the expression of E-cadherin (CDH1) in Hereditary Diffuse Gastric Cancer". Annual Meeting Portuguese Society of Human Genetics. Lisbon, Portugal, November 2008
74. "Gastric cancer". Seminars in Biopathology. Faculty of Medicine, Porto, Portugal, January 2008.
75. "Hereditary Diffuse Gastric Cancer (HDGC): The model of E-Cadherin (CDH1)". VuMC, Amsterdam, The Netherlands, October 2007
76. "BRAF and KRAS activating mutations in colorectal carcinogenesis. SINAL – 1st National Meeting on Signal Transduction. Lisbon, Portugal, March 2007
77. "*KRAS* and *BRAF* in gastrointestinal neoplasia". INSERM. Paris, France, May 2004
78. "Distinct patterns of KRAS mutations in colorectal carcinomas according to germline Mismatch Repair defects and hMLH1 methylation status". XIII Porto Cancer Meeting: Mismatch repair genes, Microssatellite Instability, and Cancer. Porto, Portugal, May 2004
79. "KRAS and BRAF in MSI gastric and colorectal carcinomas". 10th Multidisciplinary Meeting in Oncology. Lisbon, Portugal, April 2004
80. "Genetic factors of hereditary gastric cancer". Meeting on psicho-social and ethical aspects of genetic testing: neurological diseases and hereditary cancer. Porto, Portugal, June 2002

Organization of Meetings, Seminars and Courses

- Co-Organizer of the "2nd Spring Course in Hereditary Cancer Genetics". Bertinoro, Italy; April 2018
- 2017-2022: Co-Organizer, ESHG Annual Conferences
- Co-Organizer of the "1st Spring Course in Hereditary Cancer Genetics". Bertinoro, Italy; April 2016
- Chair of the Session "Gastric cancer: New insights into pathogenesis and management". UEG – United European Gastroenterology Week, Vienna Austria October 2014
- Chair of the Session "Mechanisms underlying the development of GI cancer". UEG – United European Gastroenterology Week, Vienna Austria October 2014
- Chair of the Session "Clinical perspectives on gastric malignant tumours". UEG – United European Gastroenterology Week, Vienna Austria October 2014
- Organizer of the European Human Genetics Conference 2013. Paris, France; June 2013
- Organizer of the Annual Meeting of the Portuguese Society of Human Genetics. Porto, Portugal; Nov 2012
- Organizer of the European Human Genetics Conference 2012. Nuremberg, Germany; June 2012
- Chair of the "Cancer Genetics" session, The European Human Genetics Conference 2012. Nuremberg, Germany; June 2012
- Organizer of the European Human Genetics Conference 2011. Amsterdam, The Netherlands; May 2011
- Organizer of the Annual Meeting of the Portuguese Society of Human Genetics. Lisbon, Portugal; Nov 2011
- Chair of the "Cancer Genetics" session, The European Human Genetics Conference 2011. Amsterdam, The Netherlands; May 2011
- Chair of the "Cancer Genomes" session, The European Human Genetics Conference 2011. Amsterdam, The Netherlands, May 2011
- Organizer of the European Human Genetics Conference 2010. Gothenburg, Sweden; June 2010
- Organizer of the Annual Meeting of the Portuguese Society of Human Genetics. Coimbra, Portugal; Nov 2010
- Organizer of the RNA Symposium- 17th National Congress of Biochemistry. Porto, Portugal; Sept 2010
- Chair of the "Cancer Genetics" session, The European Human Genetics Conference 2010. Gothenburg, Sweden; June 2010
- Chair of the "Long Distance Regulation session", The European Human Genetics Conference 2010. Gothenburg, Sweden; June 2010
- Chair of the SINAL 2010 – 4th National Meeting on Signal Transduction. Univ. of Algarve; Portugal; May 2010
- Chair of the SINAL 2009 – 3nd National Meeting on Signal Transduction. Univ. of Aveiro, Portugal; May 2009
- Organizer of the SINAL 2008 – 2nd National Meeting on Signal Transduction. Institute for Molecular and Cell Biology (IBMC), Porto, Portugal; May 2008
- Organizer of the XIII Edition Porto Cancer Meeting "Mismatch repair genes, Microsatellite instability, and Cancer". IPATIMUP; Porto, Portugal; May 2004
- Organizer of the XI Edition Porto Cancer Meeting "Familial and hereditary gastric cancer –Meeting of the International Gastric Cancer Linkage Consortium (IGCLC)". IPATIMUP; Porto, Portugal; May 2002

Memberships of scientific societies

- *2017-Present:* Sociedade Portuguesa de Genética - SPG
- *2016-Present:* European Society for Medical Oncology – ESMO
- *2014-Present:* Portuguese Association for Cancer research – ASPIC
- *2014-Present:* Grupo Español de Investigation en Vesículas Extracelulares - GEIVEX
- *2014-Present:* European Association for Cancer research – EACR
- *2013-Present:* European Society of Human Genetics – ESHG
- *2003-Present:* Portuguese Society of Human Genetics – SPGH

Prizes and awards (personal and to the team)

- SPGH Meeting "Prof. Doutor Amândio Tavares, FWA Award" for the best basic research work in Oncogenetics and Public Services in PT, 2017 (to Luzia Garrido)
- V Aeicbas Biomedical Congress / ICBAS "Best Poster Award" in PT, 2017 (to Celina São José)
- Portuguese Society of Oncology for the best basic research work in Oncobiology in PT, 2016 (to Joana Carvalho)
- SPGH Meeting "ESHG Award" for the best basic research work in Cancer Genetics in PT 2016 (to Ana Valente)
- SPGH Meeting "Young Investigator Award" for best basic research work in Human Genetics in PT 2016
- No Stomach For Cancer Foundation Award 2014 (to Joana Carvalho)
- ESHG Meeting "ESHG Poster Award" on basic research work in Human Genetics in Europe, 2011 (to Joana Carvalho)
- 6th Intern. Medical Postgraduate Conference for best PhD work in Europe, 2009 (to Joana Carvalho)
- SPGH Meeting "Young Investigator Award" for best basic research work in Human Genetics in PT 2004 (to Rachid Karam)
- Labmed Prize for Research in health, 2003 (co-author)
- SPGH Meeting "Young Investigator Award" for best basic research work in Human Genetics in PT 2002 (to Carla Oliveira)
- Labmed 2nd Prize for Research in health, 2001 (co-author)
- Portuguese Rotary Club Portugal Prize for best Research work in Oncobiology in Portugal 1998 (to Carla Oliveira)
- Portuguese Society Gastroenterology Prize for best basic research work in Oncobiology in Portugal, 1998 (to Carla Oliveira)

Outreach activities

- Participated in more than 40 interviews/documentaries broadcasted on TV, Radio, Internet and Newspapers over the last 15 years.
- One of the 100 Portuguese female scientists featured in the Book "Mulheres na Ciência" CiênciaViva 2016
- Organized/Participated in several public sessions about science with school kids
- Organized/Participated in several public sessions about hereditary cancer with patients' associations

Career breaks

27/06/2006: Birth of daughter Sara de Oliveira Maia, 27th June 2006 (Maternity leave)
15/09/2010: Birth of son José Miguel de Oliveira da Maia, 15th September 2010 (Maternity leave)

Recent research highlights (from 2008 onwards and as as financially independent researcher)

- **H-INDEX = 44** (SCOPUS/ResearcherID) or **53** (GoogleScholar)
- **PUBLICATIONS: 119 peer-reviewed articles** in the fields of Human Genetics and Molecular Oncology
- **Accumulated Impact Factor**: 682.026
- **Number of citations** (March 2018): 6107 times (5527 excluding self-citations SCOPUS/ResearcherID) or >9780 times (GoogleScholar)

- After obtaining financial independence in 2008, the PI was recognized as **worldwide expert in E-cadherin related diseases**, particularly Sporadic gastric cancer and Hereditary Diffuse Gastric Cancer syndrome (**HDGC**) and published **70 publications** cited **>1830 times** (SCOPUS/ResearcherID).

- The PI and her team pioneered the identification of germline CDH1 deletions as the cause of this syndrome (HMG2009) and later associated for the first time the phenotype of germline Allele-specific CDH1 downregulation to families lacking genetic diagnosis (HMG2010). Both discoveries are now integrated in the genetic diagnosis offered worldwide to HDGC families.

- The team has bioinformatically characterized cadherin superfamily introns (EJHG2012) and pioneered the discovery of novel mRNAs arising from CDH1 intron 2 (HMG2012).

- The PI and her team have identified and characterized new epigenetic mechanisms causing E-cadherin protein functional deregulation in 40% of gastric cancers (JPathol2012) and disclosed CDH1 coding structural alterations, predicting poor survival in gastric cancer (JCO2013).

- The team has disclosed the epigenetic mechanism controlling expression of a novel immunomodulator in gastric cancer (SciRep2016).

- The PI published a commissioned and seminal article about genetic susceptibility, pathology and implications for management in Familial Gastric Cancer (LancetOncol2015).

Complete list of publication of Carla Oliveira 27.03.2018

Oliveira C position in each paper reference has been highlighted in bold and underlined (Oliveira C)
Paper correspondence has been highlighted with (#);
Co-authorship has been highlighted with an asterisk (*).

2018

1. Mafalda Santos, Patricia M. Pereira, A. Sofia Varanda, Joana Carvalho, Mafalda Azevedo, Denisa D. Mateus, Nuno Mendes, Patricia Oliveira, Fábio Trindade, Marta Teixeira Pinto, Renata Bordeira-Carriço, Fátima Carneiro, Rui Vitorino, **Carla Oliveira** & Manuel A. S. Santos. Codon misreading tRNAs promote tumor growth in mice, **RNA Biology 2018**, DOI: 10.1080/15476286.2018.1454244

2. Weren RDA, van der Post RS, Vogelaar IP, van Krieken JH, Spruijt L, Lubinski J, Jakubowska A, Teodorczyk U, Aalfs CM, van Hest LP, **Oliveira C**, Kamping EJ, Schackert HK, Ranzani GN, Gómez García EB, Hes FJ, Holinski-Feder E, Genuardi M, Ausems MGEM, Sijmons RH, Wagner A, van der Kolk LE, Cats A, Bjørnevoll I, Hoogerbrugge N, Ligtenberg MJL. Role of germline aberrations affecting CTNNA1, MAP3K6 and MYD88 in gastric cancer susceptibility. **J Med Genet. 2018** Jan 12. pii: jmedgenet-2017-104962. doi: 10.1136/jmedgenet-2017-104962. [Epub ahead of print] PubMed PMID: 29330337. [ORIGINAL MANUSCRIPT]

3. Pedro G. Ferreira, Manuel Muñoz-Aguirre, Ferran Reverter, Caio P. Sá Godinho, Abel Sousa, Alicia Amadoz, Reza Sodaei, Marta R. Hidalgo, Dmitri Pervouchine, Jose Carbonell-Caballero, Ramil Nurtdinov, Alessandra Breschi, Raziel Amador, Patrícia Oliveira, Cankut Çubuk, João Curado, François Aguet, **Oliveira C**, Joaquin Dopazo, Michael Sammeth, Kristin G. Ardlie & Roderic Guigó#. The effects of death and post-mortem coldischemia on human tissue transcriptomes. **Nature Communications** 9:490 (2018) doi:10.1038/s41467-017-02772-x [ORIGINAL MANUSCRIPT]

4. Bianca N. Lourenço, Nora Springer, Daniel Ferreira, **Oliveira C**, Pedro L. Granja, Claudia Fischbach. CD44v6 increases gastric cancer malignant phenotype by modulating adipose stromal cell-mediated ECM remodelling. In Press in **Integrative Biology. 2018** Feb. doi: 10.1039/C7IB00179G [ORIGINAL MANUSCRIPT]

5. Joana Lima, Laura Cerqueira, **Oliveira C**, Nuno Filipe Azevedo. Anti-miRNA oligonucleotides: a comprehensive guide for design. In Press in **RNA Biology.** [REVIEW MANUSCRIPT]

6. Kennedy PJ, **Oliveira C**, Granja PL, Sarmento B. Monoclonal antibodies: technologies for early discovery and engineering. **Crit Rev Biotechnol. 2018** May; 38(3):394-408. doi: 10.1080/07388551.2017.1357002. Epub 2017 Aug 8. PubMed PMID: 28789584. [REVIEW MANUSCRIPT]

2017

7. Korsak B, Almeida GM, Rocha S, Pereira C, Mendes N, Osório H, Pereira PMR, Rodrigues JMM, Schneider RJ, Sarmento B, Tomé JPC*, **Oliveira C**#. Porphyrin modified trastuzumab improves efficacy of HER2 targeted photodynamic therapy of gastric cancer. **Int J Cancer. 2017** Oct 1;141(7):1478-1489. doi: 10.1002/ijc.30844. Epub 2017 Jul 10. PubMed PMID: 28639285 [ORIGINAL MANUSCRIPT]

8. Gullo I, Carneiro F, **Oliveira C**, Almeida GM. Heterogeneity in Gastric Cancer: From Pure Morphology to Molecular Classifications. **Pathobiology. 2017** Jun 16. doi: 10.1159/000473881. [Epub ahead of print] PubMed PMID: 28618420. [ORIGINAL MANUSCRIPT]

9. Kennedy PJ, **Oliveira C**, Granja PL, Sarmento B. Antibodies and associates: Partners in targeted drug delivery. **Pharmacol Ther. 2017** Sep;177:129-145. doi: 10.1016/j.pharmthera.2017.03.004. Epub 2017 Mar 14. Review. PubMed PMID: 28315359. [REVIEW MANUSCRIPT]

10. Vogelaar IP, van der Post RS, van Krieken JHJ, Spruijt L, van Zelst-Stams WA, Kets CM, Lubinski J, Jakubowska A, Teodorczyk U, Aalfs CM, van Hest LP, Pinheiro H, **Oliveira C**, Jhangiani SN, Muzny DM, Gibbs RA, Lupski JR, de Ligt J, Vissers LELM, Hoischen A, Gilissen C, van de Vorst M, Goeman JJ, Schackert HK, Ranzani GN, Molinaro V, Gómez García EB, Hes FJ, Holinski-Feder E, Genuardi M, Ausems MGEM, Sijmons RH, Wagner A, van der Kolk LE, Bjørnevoll I, Høberg-Vetti H, van Kessel AG, Kuiper RP, Ligtenberg MJL, Hoogerbrugge N. Unraveling genetic predisposition to familial or early onset gastric cancer using germline whole-exome sequencing. **Eur J Hum Genet. 2017** Sep 6. doi: 10.1038/ejhg.2017.138. PubMed PMID: 28875981; PubMed Central PMCID: PMC5643972. [ORIGINAL NETWORKING MANUSCRIPT]

11. Laundos TL, Silva J, Assunção M, Quelhas P, Monteiro C, **Oliveira C**, Oliveira MJ, Pêgo AP, Amaral IF. Rotary orbital suspension culture of embryonic stem cell-derived neural stem/progenitor cells: impact of hydrodynamic culture on aggregate yield, morphology and cell phenotype. **J Tissue Eng Regen Med. 2017** Aug;11(8):2227-2240. doi:10.1002/term.2121. Epub 2016 Feb 15. PubMed PMID:26880706. [ORIGINAL NETWORKING MANUSCRIPT]

2016

12. Oliveira P, Carvalho J, Rocha S, Azevedo M, Reis I, Camilo V, Sousa B, Valente S, Paredes J, Almeida R, Huntsman D, **Oliveira C**#. Dies1/VISTA expression loss is a recurrent event in gastric cancer due to epigenetic regulation. **Sci Rep. 2016** Oct 10;6:34860. doi: 10.1038/srep34860. PubMed PMID: 27721458; PubMed Central PMCID:PMC5056517 [ORIGINAL MANUSCRIPT]

13. van der Post RS*, Gullo I*, **Oliveira C**, Tang LH, Grabsch HI, O'Donovan M, Fitzgerald RC, van Krieken H, Carneiro F. Histopathological, Molecular, and Genetic Profile of Hereditary Diffuse Gastric Cancer: Current Knowledge and Challenges for the Future. **Adv Exp Med Biol. 2016**;908:371-91. doi:10.1007/978-3-319-41388-4_18. PubMed PMID: 27573781. [ORIGINAL MANUSCRIPT]

14. Bidarra SJ, Oliveira P, Rocha S, Saraiva DP, **Oliveira C***#, Barrias CC*. A 3D in vitro model to explore the inter-conversion between epithelial and mesenchymal states during EMT and its reversion. **Sci Rep. 2016** Jun 3;6:27072. doi:10.1038/srep27072. PubMed PMID: 27255191. [ORIGINAL MANUSCRIPT]

15. Fais S, O'Driscoll L, Borras FE, Buzas E, Camussi G, Cappello F, Carvalho J, Cordeiro da Silva A, Del Portillo H, El Andaloussi S, Ficko Trček T, Furlan R, Hendrix A, Gursel I, Kralj-Iglic V, Kaeffer B, Kosanovic M, Lekka ME, Lipps G, Logozzi M, Marcilla A, Sammar M, Llorente A, Nazarenko I, **Oliveira C**, Pocsfalvi G, Rajendran L, Raposo G, Rohde E, Siljander P, van Niel G, Vasconcelos MH, Yáñez-Mó M, Yliperttula ML, Zarovni N, Zavec AB, Giebel B. Evidence-Based Clinical Use of Nanoscale Extracellular Vesicles in Nanomedicine. **ACS Nano. 2016** Apr 26;10(4):3886-99. doi:10.1021/acsnano.5b08015. Epub 2016 Mar 15. PubMed PMID: 26978483. [REVIEW MANUSCRIPT]

16. Vogelaar IP, Ligtenberg MJ, van der Post RS, de Voer RM, Kets CM, Jansen TJ, Jacobs L, Schreibelt G; **International Gastric Cancer Genetics Group**, de Vries IJ, Netea MG, Hoogerbrugge N. Recurrent candidiasis and early-onset gastric cancer in a patient with a genetically defined partial MYD88 defect. **Fam Cancer. 2016** Apr;15(2):289-96. doi: 10.1007/s10689-015-9859-z. PubMed PMID: 26700889; PubMed Central PMCID: PMC4803817. [ORIGINAL NETWORKING MANUSCRIPT]

17. Martins-Marques T, Pinho MJ, Zuzarte M, **Oliveira C**, Pereira P, Sluijter JP, Gomes C, Girao H. Presence of Cx43 in extracellular vesicles reduces the cardiotoxicity of the anti-tumour therapeutic approach with doxorubicin. **J Extracell Vesicles. 2016** Sep 29;5:32538. doi: 10.3402/jev.v5.32538. eCollection 2016. PubMed PMID: 27702427; PubMed Central PMCID: PMC5045474.

2015

18. Queirós P, Pinheiro H, Carvalho J, Oliveira P, Gullo I, Carneiro F, Almeida GM, **Oliveira C#**. KRAS mutations in microsatellite instable gastric tumours: impact of targeted treatment and intratumoural heterogeneity. **Virchows Arch. 2015** Oct;467(4):383-92. doi: 10.1007/s00428-015-1823-7. Epub 2015 Aug 29. PubMed PMID: 26318594. [ORIGINAL MANUSCRIPT]

19. Hansford S, Kaurah P, Li-Chang H, Woo M, Senz J, Pinheiro H, Schrader KA, Schaeffer DF, Shumansky K, Zogopoulos G, Santos TA, Claro I, Carvalho J, Nielsen C, Padilla S, Lum A, Talhouk A, Baker-Lange K, Richardson S, Lewis I, Lindor NM, Pennell E, MacMillan A, Fernandez B, Keller G, Lynch H, Shah SP, Guilford P, Gallinger S, Corso G, Roviello F, Caldas C, **Oliveira C**, Pharoah PD, Huntsman DG. Hereditary Diffuse Gastric Cancer Syndrome: CDH1 Mutations and Beyond. **JAMA Oncol. 2015** Apr;1(1):23-32. doi: 10.1001/jamaoncol.2014.168. PubMed PMID: 26182300. [ORIGINAL MANUSCRIPT]

20. van der Post RS, Vogelaar IP, Carneiro F, Guilford P, Huntsman D, Hoogerbrugge N, Caldas C, Schreiber KE, Hardwick RH, Ausems MG, Bardram L, Benusiglio PR, Bisseling TM, Blair V, Bleiker E, Boussioutas A, Cats A, Coit D, DeGregorio L, Figueiredo J, Ford JM, Heijkoop E, Hermens R, Humar B, Kaurah P, Keller G, Lai J, Ligtenberg MJ, O'Donovan M, **Oliveira C**, Pinheiro H, Ragunath K, Rasenberg E, Richardson S, Roviello F, Schackert H, Seruca R, Taylor A, Ter Huurne A, Tischkowitz M, Joe ST, van Dijck B, van Grieken NC, van Hillegersberg R, van Sandick JW, Vehof R, van Krieken JH, Fitzgerald RC. Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers. **J Med Genet. 2015** Jun;52(6):361-74. doi: 10.1136/jmedgenet-2015-103094.Epub 2015 May 15. Review. PubMed PMID: 25979631; PubMed Central PMCID:PMC4453626. [REVIEW MANUSCRIPT]

21. **Oliveira C**, Pinheiro H, Figueiredo J, Seruca R, Carneiro F. Familial Gastric Cancer: genetic susceptibility, pathology and implications for management. **Lancet Oncol. 2015** Feb;16(2):e60-e70. doi: 10.1016/S1470-2045(14)71016-2. Review. PubMed PMID: 25638682. [REVIEW MANUSCRIPT]

22. Magalhães A, Marcos-Pinto R, Nairn AV, Dela Rosa M, Ferreira RM, Junqueira-Neto S, Freitas D, Gomes J, Oliveira P, Santos MR, Marcos NT, Xiaogang W, Figueiredo C, **Oliveira C**, Dinis-Ribeiro M, Carneiro F, Moremen KW, David L, Reis CA. Helicobacter pylori chronic infection and mucosal inflammation switches the human gastric glycosylation pathways. **Biochim Biophys Acta. 2015** Sep;1852(9):1928-39. doi:10.1016/j.bbadis.2015.07.001. Epub 2015 Jul 2. PubMed PMID: 26144047. PubMed Central PMCID: PMC4638172. [ORIGINAL NETWORKING MANUSCRIPT]

23. Alves S, Castro L, Fernandes MS, Francisco R, Castro P, Priault M, Chaves SR, Moyer MP, **Oliveira C**, Seruca R, Côrte-Real M, Sousa MJ, Preto A. Colorectal cancer-related mutant KRAS alleles function as positive regulators of autophagy. **Oncotarget. 2015** Oct 13;6(31):30787-802. doi: 10.18632/oncotarget.5021. PubMed PMID: 26418750; PubMed Central PMCID: PMC4741568. [ORIGINAL NETWORKING MANUSCRIPT]

24. Carvalho J, **Oliveira C**. Extracellular Vesicles - Powerful Markers of Cancer EVolution. Front Immunol. 2015 Jan 12;5:685. doi: 10.3389/fimmu.2014.00685. eCollection 2014. PubMed PMID: 25628624; PubMed Central PMCID: PMC4290688 [REVIEW MANUSCRIPT]

25. Caires HR, Gomez-Lazaro M, Oliveira CM, Gomes D, Mateus DD, **Oliveira C**, Barrias CC, Barbosa MA, Almeida CR. Finding and tracing human MSC in 3D microenvironments with the photoconvertible protein Dendra2. **Sci Rep. 2015** May 14;5:10079. doi: 10.1038/srep10079. PubMed PMID: 25974085; PubMed Central PMCID: PMC4431349. [ORIGINAL NETWORKING MANUSCRIPT]

26. Pinheiro H, Oliveira P, **Oliveira C**. Hereditary cancer risk assessment: challenges for the next-gen sequencing era. **Front Oncol. 2015** Mar 23;5:62. doi: 10.3389/fonc.2015.00062. eCollection 2015. Review. PubMed PMID: 25853090; PubMed Central PMCID: PMC4370032. [REVIEW MANUSCRIPT]

27. Yáñez-Mó M, Siljander PR, Andreu Z, Zavec AB, Borràs FE, Buzas EI, Buzas K, Casal E, Cappello F, Carvalho J, Colás E, Cordeiro-da Silva A, Fais S, Falcon-Perez JM, Ghobrial IM, Giebel B, Gimona M, Graner M, Gursel I, Gursel M, Heegaard NH, Hendrix A, Kierulf P, Kokubun K, Kosanovic M, Kralj-Iglic V, Krämer-Albers EM, Laitinen S, Lässer C, Lener T, Ligeti E, Linē A, Lipps G, Llorente A, Lötvall J, Manček-Keber M, Marcilla A, Mittelbrunn M, Nazarenko I, Nolte-'t Hoen EN, Nyman TA, O'Driscoll L, Olivan M, **Oliveira C**, Pállinger É, Del Portillo HA, Reventós J, Rigau M, Rohde E, Sammar M, Sánchez-Madrid F, Santarém N, Schallmoser K, Ostenfeld MS, Stoorvogel W, Stukelj R, Van der Grein SG, Vasconcelos MH, Wauben MH, De Wever O. Biological properties of extracellular vesicles and their physiological functions. **J Extracell Vesicles. 2015** May 14;4:27066. doi: 10.3402/jev.v4.27066. eCollection 2015. PubMed PMID: 25979354; PubMed Central PMCID: PMC4433489. [REVIEW MANUSCRIPT]

2014

28. Gaston D*, Hansford S*, **Oliveira C**, Nightingale M, Pinheiro H, Macgillivray C, Kaurah P, Rideout AL, Steele P, Soares G, Huang WY, Whitehouse S, Blowers S, LeBlanc MA, Jiang H, Greer W, Samuels ME, Orr A, Fernandez CV, Majewski J, Ludman M, Dyack S, Penney LS, McMaster CR, Huntsman D, Bedard K. Germline mutations in MAP3K6 are associated with familial gastric cancer. **PLoS Genet. 2014** Oct 23;10(10):e1004669. doi: 10.1371/journal.pgen.1004669. eCollection 2014 Oct. PubMed PMID: 25340522; PubMed Central PMCID: PMC4207611 [ORIGINAL MANUSCRIPT]

29. Bordeira-Carriço R, Ferreira D, Mateus DD, Pinheiro H, Pêgo AP, Santos MA, **Oliveira C#**. Rescue of wild-type E-cadherin expression from nonsense-mutated cancer cells by a suppressor-tRNA. **Eur J Hum Genet. 2014** Sep;22(9):1085-92. doi:10.1038/ejhg.2013.292. Epub 2014 Jan 15. PubMed PMID: 24424122; PubMed Central PMCID: PMC4135406 [ORIGINAL MANUSCRIPT]

30. Durães C, Almeida GM, Seruca R, **Oliveira C#**, Carneiro F. Biomarkers for gastric cancer: prognostic, predictive or targets of therapy? **Virchows Arch. 2014** Mar;464(3):367-78. doi: 10.1007/s00428-013-1533-y. Epub 2014 Feb 1. PubMed PMID: 24487788. [REVIEW MANUSCRIPT]

31. Pinheiro H*, **Oliveira C***, Seruca R, Carneiro F. Hereditary diffuse gastric cancer - pathophysiology and clinical management. **Best Pract Res Clin Gastroenterol. 2014** Dec;28(6):1055-68. Epub 2014 Sep 28. PubMed PMID: 25439071. [REVIEW MANUSCRIPT]

32. Ferreira AM, Tuominen I, Sousa S, Gerbens F, van Dijk-Bos K, Osinga J, Kooi KA, Sanjabi B, Esendam C, **Oliveira C**, Terpstra P, Hardonk M, van der Sluis T, Zazula M, Stachura J, van der Zee AG, Hollema H, Sijmons RH, Aaltonen LA, Seruca R, Hofstra RM, Westers H. New target genes in endometrial tumors show a role for the estrogen-receptor pathway in microsatellite-unstable cancers. **Hum Mutat. 2014** Dec;35(12):1514-23. doi: 10.1002/humu.22700. PubMed PMID: 25231886. [ORIGINAL MANUSCRIPT]

33. Carneiro F, Wen X, Seruca R, **Oliveira C#**. Familial gastric carcinoma. **Diagnostic Histopathology. 2014** April; 20(6):239-246. doi: 10.1016/j.mpdhp.2014.03.010 [REVIEW MANUSCRIPT]

2013

34. Corso G*, Carvalho J*, Marrelli D, Vindigni C, Carvalho B, Seruca R, Roviello F, **Oliveira C#**. Somatic mutations and deletions of the E-cadherin gene predict poor survival of gastric cancer patients. **J Clin Oncol. 2013** Mar 1;31(7):868-75. doi: 10.1200/JCO.2012.44.4612. Epub 2013 Jan 22. PubMed PMID: 23341533. [ORIGINAL MANUSCRIPT]

35. Pinho SS, Carvalho S, Marcos-Pinto R, Magalhães A, **Oliveira C**, Gu J, Dinis-Ribeiro M, Carneiro F, Seruca R, Reis CA. Gastric cancer: adding glycosylation to the equation. **Trends Mol Med. 2013** 2013 Nov;19(11):664-76. doi:10.1016/j.molmed.2013.07.003. Epub 2013 Aug 8. Review. PubMed PMID: 23932995. [REVIEW MANUSCRIPT]

36. Fernandes MS, Carneiro F, **Oliveira C**, Seruca R. Colorectal cancer and RASSF family - a special emphasis on RASSF1A. **Int J Cancer. 2013** Jan 15;132(2):251-8. doi: 10.1002/ijc.27696. Epub 2012 Jul 14. Review. PubMed PMID: 22733432. [REVIEW MANUSCRIPT]

37. **Oliveira C#**,, Pinheiro H, Figueiredo J, Seruca R, Carneiro F. E-cadherin alterations in hereditary disorders with emphasis on hereditary diffuse gastric cancer. **Prog Mol Biol Transl Sci.** 2013;116:337-59. doi:10.1016/B978-0-12-394311-8.00015-7. PubMed PMID: 23481202. [REVIEW MANUSCRIPT]

38. Carneiro P, Figueiredo J, Bordeira-Carriço R, Fernandes MS, Carvalho J, **Oliveira C#**, Seruca R. Therapeutic targets associated to E-cadherin dysfunction in gastric cancer. **Expert Opin Ther Targets. 2013** Oct;17(10):1187-201. doi: 10.1517/14728222.2013.827174. Epub 2013 Aug 19. Review. PubMed PMID: 23957294. [REVIEW MANUSCRIPT]

39. de-Freitas-Junior JC, Carvalho S, Dias AM, Oliveira P, Cabral J, Seruca R, **Oliveira C**, Morgado-Díaz JA, Reis CA, Pinho SS. Insulin/IGF-I signaling pathways enhances tumor cell invasion through bisecting GlcNAc N-glycans modulation. An interplay with E-cadherin. **PLoS One. 2013** Nov 25;8(11):e81579. doi: 10.1371/journal.pone.0081579. eCollection 2013. PubMed PMID: 24282611; PubMed Central PMCID: PMC3839884. [ORIGINAL NETWORKING MANUSCRIPT]

40. **Oliveira C***, Seruca R, Hoogerbrugge N, Ligtenberg M, Carneiro F. Clinical utility gene card for: Hereditary diffuse gastric cancer (HDGC). **Eur J Hum Genet 2013** Aug;21(8). doi: 10.1038/ejhg.2012.247. Epub 2013 Feb 27. PubMed PMID: 23443028; PubMed Central PMCID: PMC3722670. [ORIGINAL MANUSCRIPT]

41. Pereira B, Sousa S, Barros R, Carreto L, Oliveira P, **Oliveira C**, Chartier NT, Plateroti M, Rouault JP, Freund JN, Billaud M, Almeida R. CDX2 regulation by the RNA-binding protein MEX3A: impact on intestinal differentiation and stemness. **Nucleic Acids Res. 2013** Apr;41(7):3986-99. doi: 10.1093/nar/gkt087. Epub 2013 Feb 13. PubMed PMID: 23408853; PubMed Central PMCID: PMC3627580. [ORIGINAL MANUSCRIPT]

2012

42. Paredes J, Figueiredo J, Albergaria A, Oliveira P, Carvalho J, Ribeiro AS, Caldeira J, Costa AM, Simões-Correia J, Oliveira MJ, Pinheiro H, Pinho SS, Mateus R, Reis CA, Leite M, Fernandes MS, Schmitt F, Carneiro F, Figueiredo C, **Oliveira C**, Seruca R. Epithelial E- and P-cadherins: Role and clinical ignificance in cancer. **Biochim Biophys Acta. 2012** Dec;1826(2):297-311. doi:10.1016/j.bbcan.2012.05.002. Epub 2012 May 19. Review. PubMed PMID: 22613680. [REVIEW MANUSCRIPT]
43. Carvalho J, Grieken NCv, Pereira PM, Sousa S, Tijssen M, Buffart TE, Diosdado D, Grabsch H, Santos MA, Meijer G, Seruca R, Carvalho B, **Oliveira C**#. Lack of microRNA-101 causes E-cadherin functional deregulation through EZH2 up-regulation in intestinal gastric cancer. **J Pathol. 2012** Sep;228(1):31-44. doi: 10.1002/path.4032. Epub 2012 May 23. PubMed PMID: 22450781. [ORIGINAL MANUSCRIPT]
44. Kluijt I, Siemerink EJ, Ausems MG, van Os TA, de Jong D, Simões-Correia J, van Krieken JH, Ligtenberg MJ, Figueiredo J, van Riel E, Sijmons RH, Plukker JT, van Hillegersberg R, Dekker E, **Oliveira C**, Cats A, Hoogerbrugge N; on behalf of the Dutch Working Group on Hereditary Gastric Cancer. CDH1-related hereditary diffuse gastric cancer syndrome: Clinical variations and implications for counseling. **Int J Cancer. 2012** Jul 15;131(2):367-76. doi: 10.1002/ijc.26398. Epub 2011 Oct 23. PubMed PMID: 22020549. [ORIGINAL NETWORKING MANUSCRIPT]
45. Pinho SS*, Oliveira P*, Cabral J, Carvalho S, Seruca R, Reis C*, **Oliveira C***#. Loss and recovery of Mgat3 and GnT-III Mediated E-cadherin N-glycosylation is a mechanism involved in epithelial-mesenchymal-epithelial transitions. **PLoS One. 2012**;7(3):e33191. doi: 10.1371/journal.pone.0033191. Epub 2012 Mar 13. PubMed PMID: 22427986; PubMed Central PMCID: PMC3302839. [ORIGINAL MANUSCRIPT]
46. Carneiro P, Fernandes MS, Figueiredo J, Caldeira J, Carvalho J, Pinheiro H, Leite M, Melo S, Oliveira P, Simões-Correia J, Oliveira MJ, Carneiro F, Figueiredo C, Paredes J, **Oliveira C**, Seruca R. E-cadherin dysfunction in gastric cancer - Cellular consequences, clinical applications and open questions. **FEBS Lett. 2012** Aug 31;586(18):2981-9. doi: 10.1016/j.febslet.2012.07.045. Epub 2012 Jul 25. Review. PubMed PMID: 22841718. [REVIEW MANUSCRIPT]
47. Lopes N, Carvalho J, Durães C, Sousa B, Gomes M, Costa JL, **Oliveira C**, Paredes J, Schmitt F. 1Alpha, 25-dihydroxyvitamin D3 induces de novo E-cadherin expression in triple-negative breast cancer cells by CDH1-promoter demethylation. **Anticancer Res. 2012** Jan;32(1):249-57. PubMed PMID: 22213313. [ORIGINAL NETWORKING MANUSCRIPT]
48. Simões-Correia J, Figueiredo J, Lopes R, Stricher F, **Oliveira C**, Serrano L, Seruca R. (2012) E-Cadherin Destabilization Accounts for the Pathogenicity of Missense Mutations in Hereditary Diffuse Gastric Cancer. **PLoS ONE. 2012**; 7(3): e33783 doi:10.1371/journal.pone.0033783. Epub 2012 Mar 21. PubMed PMID: 22470475; PubMed Central PMCID: PMC3309996 [ORIGINAL NETWORKING MANUSCRIPT]
49. Bordeira-Carriço R, Pêgo AP, Santos M, **Oliveira C**#. Cancer syndromes and therapy by stop-codon readthrough. **Trends Mol Med. 2012** Nov;18(11):667-78. doi:10.1016/j.molmed.2012.09.004. Epub 2012 Oct 6. Review. PubMed PMID: 23044248. [REVIEW MANUSCRIPT]
50. Caldeira J, Simões-Correia J, Paredes J, Pinto MT, Sousa S, Corso G, Marrelli D, Roviello F, Pereira PS, Weil D, **Oliveira C**, Casares F, Seruca R. (2011): CPEB1, a novel gene silenced in Gastric Cancer - a Drosophila approach. **Gut. 2012** Aug;61(8):1115-23. doi: 10.1136/gutjnl-2011-300427. Epub 2011 Nov 3. PubMed PMID:22052064. [ORIGINAL NETWORKING MANUSCRIPT]
51. Pinheiro H, Carvalho J, Oliveira P, Ferreira D, Pinto MT, Osório H, Licastro D, Bordeira-Carriço R, Jordan P, Lazarevic D, Sanges R, Stupka E, Huntsman D, Seruca R, **Oliveira C**#. Transcription initiation arising from E-cadherin/CDH1 intron2: a novel protein isoform that increases gastric cancer cell invasion and angiogenesis. **Hum Mol Genet. 2012** Oct 1;21(19):4253-69. doi: 10.1093/hmg/dds248. Epub 2012 Jun 29. PubMed PMID: 22752307. [ORIGINAL MANUSCRIPT]
52. Oliveira P, Sanges R, Huntsman DG, Stupka E, **Oliveira C**#. Characterization of the intronic portion of cadherin superfamily members, common cancer orchestrators. **Eur J Hum Genet. 2012** F Aug;20(8):878-83. doi: 10.1038/ejhg.2012.11. Epub 2012 Feb 8. PubMed PMID: 22317972; PubMed Central PMCID: PMC3400724. [ORIGINAL MANUSCRIPT]

2011

53. Corso G, Velho S, Paredes J, Pedrazzani C, Martins D, Milanezi F, Pascale V, Vindigni C, Pinheiro H, Leite M, Marrelli D, Sousa S, Carneiro F, **Oliveira C**, Roviello F, Seruca R. Oncogenic mutations in gastric cancer with microsatellite instability. **Eur J Cancer. 2011** Feb;47(3):443-51. doi: 10.1016/j.ejca.2010.09.008. PubMed PMID: 20937558. [ORIGINAL NETWORKING MANUSCRIPT]

54. Corso G, Pedrazzani C, Pinheiro H, Fernandes E, Marrelli D, Rinnovati A, Pascale V, Seruca R, **Oliveira C#**, Roviello F. E-cadherin genetic screening and clinico-pathologic characteristics of early onset gastric cancer. **Eur J Cancer. 2011** Mar;47(4):631-9. doi: 10.1016/j.ejca.2010.10.011. Epub 2010 Nov 22. PubMed PMID: 21106365. [ORIGINAL MANUSCRIPT]

55. Leite M, Corso G, Sousa S, Milanezi F, Afonso LP, Henrique R, Soares JM, Castedo S, Carneiro F, Roviello F, **Oliveira C**, Seruca R. MSI phenotype and MMR alterations in familial and sporadic gastric cancer. **Int J Cancer. 2011** Apr 1;128(7):1606-13. doi: 10.1002/ijc.25495. Epub 2010 Jun 7. PubMed PMID: 20533283. [ORIGINAL NETWORKING MANUSCRIPT]

2010

56. da Cunha CB, **Oliveira C**, Wen X, Gomes B, Sousa S, Suriano G, Grellier M, Huntsman DG, Carneiro F, Granja PL, Seruca R. De novo expression of CD44 variants in sporadic and hereditary gastric cancer. **Lab Invest. 2010** Nov;90(11):1604-1614. doi: 10.1038/labinvest.2010.155. Epub 2010 Sep 20. PubMed PMID: 20856229. [ORIGINAL MANUSCRIPT]

57. Svrcek M, Buhard O, Colas C, Coulet F, Dumont S, Massaoudi I, Lamri A, Hamelin R, Cosnes J, **Oliveira C**, Seruca R, Gaub MP, Legrain M, Collura A, Lascols O, Tiret E, Fléjou JF, Duval A. Methylation tolerance due to an O6-methylguanine DNA methyltransferase (MGMT) field defect in the colonic mucosa: an initiating step in the development of mismatch repair-deficient colorectal cancers. **Gut. 2010** Nov;59(11):1516-1526. doi: 10.1136/gut.2009.194787. PubMed PMID: 20947886. [ORIGINAL NETWORKING MANUSCRIPT]

58. Albergaria A, Ribeiro AS, Pinho S, Milanezi F, Carneiro V, Sousa B, Sousa S, **Oliveira C**, Machado JC, Seruca R, Paredes J, Schmitt F. ICI 182, 780 induces P-cadherin overexpression in breast cancer cells through chromatin remodelling at the promoter level: a role for C/EBPbeta in CDH3 gene activation. **Hum Mol Genet. 2010** Jul 1;19(13):2554-66. doi: 10.1093/hmg/ddq134. Epub 2010 Apr 12. PubMed PMID: 20385540. [ORIGINAL NETWORKING MANUSCRIPT]

59. Carneiro F, **Oliveira C**, Seruca R. Pathology and genetics of familial gastric cancer. **Int J Surg Pathol. 2010** Jun;18(3 Suppl):33S-36S. doi:10.1177/1066896910366463. PubMed PMID:20484258. [REVIEW MANUSCRIPT]

60. Velho S, Corso G, **Oliveira C**, Seruca R. KRAS signaling pathway alterations in microsatellite unstable gastrointestinal cancers. **Adv Cancer Res. 2010**;109:123-43. doi: 10.1016/B978-0-12-380890-5.00004-1. PubMed PMID:21070916. [REVIEW MANUSCRIPT]

61. Fitzgerald RC, Hardwick R, Huntsman D, Carneiro F, Guilford P, Blair V, Chung DC, Norton J, Ragunath K, Van Krieken JH, Dwerryhouse S, Caldas C; International Gastric Cancer Linkage Consortium. *Collaborators:* ..., **Oliveira C**, ... Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. **J Med Genet. 2010** Jul;47(7):436-44. doi: 10.1136/jmg.2009.074237. Erratum in: J Med Genet. 2011 Mar;48(3):216. Van Krieken, Nicola [corrected to Van Grieken, Nicola C]. PubMed PMID: 20591882; PubMed Central PMCID: PMC2991043. [REVIEW MANUSCRIPT]

62. Pinheiro H, Bordeira-Carriço R, Seixas S, Carvalho J, Senz J, Oliveira P, Inácio P, Gusmão L, Rocha J, Huntsman D, Seruca R, **Oliveira C#**. Allele-specific CDH1 downregulation and hereditary diffuse gastric cancer. **Hum Mol Genet. 2010** Mar 1;19(5):943-952. doi: 10.1093/hmg/ddp537. Epub 2009 Dec 4. PubMed PMID:19965908; PubMed Central PMCID: PMC2816607. [ORIGINAL MANUSCRIPT]

63. Velho S, **Oliveira C**, Paredes J, Sousa S, Leite M, Matos P, Milanezi F, Ribeiro AS, Mendes N, Licastro D, Karhu A, Oliveira MJ, Ligtenberg M, Hamelin R, Carneiro F, Lindblom A, Peltomaki P, Castedo S, Schwartz S Jr, Jordan P, Aaltonen LA, Hofstra RM, Suriano G, Stupka E, Fialho AM, Seruca R. Mixed lineage kinase 3 gene mutations in mismatch repair deficient gastrointestinal tumours. Hum Mol Genet. 2010 Feb 15;19(4):697-706. doi: 10.1093/hmg/ddp536. Epub 2009 Dec 2. PubMed PMID: 19955118; PubMed Central PMCID: PMC2807374. [ORIGINAL NETWORKING MANUSCRIPT]

2009

64. Borie C, Colas C, Dartigues P, Lazure T, Rince P, Buhard O, Folliot P, Chalastanis A, Muleris M, Hamelin R, Mercier D, **Oliveira C**, Seruca R, Chadburn A, Leblond V, Barete S, Gaïdano G, Martin A, Gaulard P, Fléjou JF, Raphael M, Duval A. The mechanisms underlying MMR deficiency in immunodeficiency-related

non-Hodgkin lymphomas are different from those in other sporadic microsatellite instable neoplasms. **Int J Cancer. 2009** Nov 15;125(10):2360-2366. doi: 10.1002/ijc.24681. PubMed PMID: 19551857. [ORIGINAL NETWORKING MANUSCRIPT]

65. Pereira B, **Oliveira C**, David L, Almeida R. CDX2 promoter methylation is not associated with mRNA expression. **Int J Cancer. 2009** Oct 1;125(7):1739-1742. doi:10.1002/ijc.24544. PubMed PMID: 19569237. [ORIGINAL NETWORKING MANUSCRIPT]
66. Gonçalves CM, Castro MA, Henriques T, Oliveira MI, Pinheiro HC, **Oliveira C**, Sreenu VB, Evans EJ, Davis SJ, Moreira A, Carmo AM. Molecular cloning and analysis of SSc5D, a new member of the scavenger receptor cysteine-rich superfamily. **Mol Immunol. 2009** Aug;46(13):2585-96. doi:10.1016/j.molimm.2009.05.006. Epub 2009 Jun 16. PubMed PMID: 19535143. [ORIGINAL NETWORKING MANUSCRIPT]
67. **Oliveira C**#, Sousa S, Pinheiro H, Karam R, Bordeira-Carriço R, Senz J, Kaurah P, Carvalho J, Pereira R, Gusmão L, Wen X, Cipriano MA, Yokota J, Carneiro F, Huntsman D, Seruca R. Quantification of epigenetic and genetic 2nd hits in CDH1 during hereditary diffuse gastric cancer syndrome progression. **Gastroenterology. 2009** Jun;136(7):2137-2148. doi: 10.1053/j.gastro.2009.02.065. Epub 2009 Mar 6. PubMed PMID: 19269290. [ORIGINAL MANUSCRIPT]
68. **Oliveira C**, Senz J, Kaurah P, Pinheiro H, Sanges R, Haegert A, Corso G, Schouten J, Fitzgerald R, Vogelsang H, Keller G, Dwerryhouse S, Grimmer D, Chin SF, Yang HK, Jackson CE, Seruca R, Roviello F, Stupka E, Caldas C, Huntsman D. Germline CDH1 deletions in hereditary diffuse gastric cancer families. **Hum Mol Genet. 2009** May 1;18(9):1545-1555. doi: 10.1093/hmg/ddp046. Epub 2009 Jan 24. PubMed PMID: 19168852; PubMed Central PMCID: PMC2667284. [ORIGINAL MANUSCRIPT]
69. **Oliveira C**, Seruca R, Carneiro F. Hereditary gastric cancer. **Best Pract Res Clin Gastroenterol. 2009**;23(2):147-57. doi: 10.1016/j.bpg.2009.02.003. PubMed PMID: 19414142. [REVIEW MANUSCRIPT]
70. Seruca R, Velho S, **Oliveira C**, Leite M, Matos P, Jordan P. Unmasking the role of KRAS and BRAF pathways in MSI colorectal tumors. **Expert Rev Gastroenterol Hepatol.** 2009 Feb;3(1):5-9. doi: 10.1586/17474124.3.1.5. PubMed PMID: 19210107. [REVIEW MANUSCRIPT]
71. Velho S, **Oliveira C**, Seruca R. KRAS mutations and anti-epidermal growth factor receptor therapy in colorectal cancer with lymph node metastases. **J Clin Oncol. 2009** Jan 1;27(1):158-9; author reply 159. doi: 10.1200/JCO.2008.20.1525. PubMed PMID: 19047277. [ORIGINAL NETWORKING MANUSCRIPT]
72. Pinto C, Veiga I, Pinheiro M, Peixoto A, Pinto A, Lopes JM, Reis RM, **Oliveira C**, Baptista M, Roque L, Regateiro F, Cirnes L, Hofstra RM, Seruca R, Castedo S, Teixeira MR. TP53 germline mutations in Portugal and genetic modifiers of age at cancer onset. **Fam Cancer. 2009**;8(4):383-390. doi: 10.1007/s10689-009-9251-y. PubMed PMID: 19468865. [ORIGINAL NETWORKING MANUSCRIPT]

2008

73. Velho S, Moutinho C, Cirnes L, Albuquerque C, Hamelin R, Schmitt F, Carneiro F, **Oliveira C**, Seruca R. BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: primary or secondary genetic events in colorectal carcinogenesis? **BMC Cancer. 2008** Sep 9;8:255. doi: 10.1186/1471-2407-8-255. PubMed PMID: 18782444; PubMed Central PMCID: PMC2553419 [ORIGINAL NETWORKING MANUSCRIPT]
74. Barber M, Murrell A, Ito Y, Maia AT, Hyland S, **Oliveira C**, Save V, Carneiro F, Paterson AL, Grehan N, Dwerryhouse S, Lao-Sirieix P, Caldas C, Fitzgerald RC. Mechanisms and sequelae of E-cadherin silencing in hereditary diffuse gastric cancer. **J Pathol. 2008** Nov;216(3):295-306. doi: 10.1002/path.2426. PubMed PMID:18788075. [ORIGINAL NETWORKING MANUSCRIPT]
75. Carneiro F, **Oliveira C**, Suriano G, Seruca R. Molecular pathology of familial gastric cancer, with an emphasis on hereditary diffuse gastric cancer. **J Clin Pathol. 2008** Jan;61(1):25-30. PubMed PMID: 17513507. [REVIEW MANUSCRIPT]
76. Preto A, Figueiredo J, Velho S, Ribeiro AS, Soares P, **Oliveira C**, Seruca R. BRAF provides proliferation and survival signals in MSI colorectal carcinoma cells displaying BRAF(V600E) but not KRAS mutations. **J Pathol. 2008** Feb;214(3):320-7. PubMed PMID: 18098337.[ORIGINAL NETWORKING MANUSCRIPT]
77. Simões-Correia J, Figueiredo J, **Oliveira C**, van Hengel J, Seruca R, van Roy F, Suriano G. Endoplasmic reticulum quality control: a new mechanism of E-cadherin regulation and its implication in cancer. **Hum Mol Genet. 2008** Nov 15;17(22):3566-76. doi: 10.1093/hmg/ddn249. Epub 2008 Sep 4. PubMed PMID: 18772194. [ORIGINAL NETWORKING MANUSCRIPT]

78. Matos P, **Oliveira C**, Velho S, Gonçalves V, da Costa LT, Moyer MP, Seruca R, Jordan P. B-Raf(V600E) cooperates with alternative spliced Rac1b to sustain colorectal cancer cell survival. **Gastroenterology. 2008** Sep;135(3):899-906. doi: 10.1053/j.gastro.2008.05.052. Epub 2008 May 22. PubMed PMID: 18602919 [ORIGINAL MANUSCRIPT]

79. Karam R, Carvalho J, Bruno I, Graziadio C, Senz J, Huntsman D, Carneiro F, Seruca R, Wilkinson MF, **Oliveira C**#. The NMD mRNA surveillance pathway downregulates aberrant E-cadherin transcripts in gastric cancer cells and in CDH1 mutation carriers. **Oncogene. 2008** Jul 10;27(30):4255-60. doi:10.1038/onc.2008.62. Epub 2008 Apr 21. PubMed PMID: 18427545. [ORIGINAL MANUSCRIPT]

80. Carneiro F, **Oliveira C**, Leite M, Seruca R. Molecular targets and biological modifiers in gastric cancer. Semin **Diagn Pathol. 2008** Nov;25(4):274-87. PubMed PMID: 19013893. [REVIEW MANUSCRIPT]

81. Woo MM, Salamanca CM, Miller M, Symowicz J, Leung PC, **Oliveira C**, Ehlen TG, Gilks CB, Huntsman D, Auersperg N. Serous borderline ovarian tumors in long-term culture: phenotypic and genotypic distinction from invasive ovarian carcinomas. **Int J Gynecol Cancer. 2008** Nov-Dec;18(6):1234-47. doi:10.1111/j.1525-1438.2007.01171.x. PubMed PMID: 18217967. [ORIGINAL NETWORKING MANUSCRIPT]

2007

82. Kaurah P, MacMillan A, Boyd N, Senz J, De Luca A, Chun N, Suriano G, Zaor S, Van Manen L, Gilpin C, Nikkel S, Connolly-Wilson M, Weissman S, Rubinstein WS, Sebold C, Greenstein R, Stroop J, Yim D, Panzini B, McKinnon W, Greenblatt M, Wirtzfeld D, Fontaine D, Coit D, Yoon S, Chung D, Lauwers G, Pizzuti A, Vaccaro C, Redal MA, **Oliveira C**, Tischkowitz M, Olschwang S, Gallinger S, Lynch H, Green J, Ford J, Pharoah P, Fernandez B, Huntsman D. Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. **JAMA. 2007** Jun 6;297(21):2360-72. Epub 2007 Jun 3. PubMed PMID: 17545690. [ORIGINAL NETWORKING MANUSCRIPT]

83. **Oliveira C**, Velho S, Moutinho C, Ferreira A, Preto A, Domingo E, Capelinha AF, Duval A, Hamelin R, Machado JC, Schwartz S Jr, Carneiro F, Seruca R. KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression. **Oncogene. 2007** Jan 4;26(1):158-63. Epub 2006 Sep 4. PubMed PMID: 16953233. [ORIGINAL MANUSCRIPT]

84. Masciari S, Larsson N, Senz J, Boyd N, Kaurah P, Kandel MJ, Harris LN, *Pinheiro HC*, Troussard A, Miron P, Tung N, **Oliveira C**, Collins L, Schnitt S, Garber JE, Huntsman D. Germline E-cadherin mutations in familial lobular breast cancer. **J Med Genet. 2007** Nov;44(11):726-31. PubMed PMID:17660459; PubMed Central PMCID: PMC2752184 [ORIGINAL NETWORKING MANUSCRIPT]

85. Svrcek M, El-Bchiri J, Chalastanis A, Capel E, Dumont S, Buhard O, **Oliveira C**, Seruca R, Bossard C, Mosnier JF, Berger F, Leteurtre E, Lavergne-Slove A, Chenard MP, Hamelin R, Cosnes J, Beaugerie L, Tiret E, Duval A, Fléjou JF. Specific clinical and biological features characterize inflammatory bowel disease associated colorectal cancers showing microsatellite instability. **J Clin Oncol. 2007** Sep Sep 20;25(27):4231-8. PubMed PMID: 17878476.. [ORIGINAL NETWORKING MANUSCRIPT]

86. Corso G, Roviello F, Paredes J, Pedrazzani C, Novais M, Correia J, Marrelli D, Cirnes L, Seruca R, **Oliveira C**, Suriano G. Characterization of the P373L E-cadherin germline missense mutation and implication for clinical management. **Eur J Surg Oncol. 2007** Nov;33(9):1061-7. PubMed PMID: 17434710. [ORIGINAL NETWORKING MANUSCRIPT]

87. Preto A, Moutinho C, Velho S, **Oliveira C**, Rebocho AP, Figueiredo J, Soares P, Lopes JM, Seruca R. A subset of colorectal carcinomas express c-KIT protein independently of BRAF and/or KRAS activation. **Virchows Arch. 2007** Jun;450(6):619-26. Epub 2007 May 9. PubMed PMID: 17487504. [ORIGINAL NETWORKING MANUSCRIPT]

2006

88. **Oliveira C**, Seruca R, Carneiro F. Genetics, pathology, and clinics of familial gastric cancer. **Int J Surg Pathol. 2006** Jan;14(1):21-33. Review. PubMed PMID:16501831. [REVIEW MANUSCRIPT]

89. Frebourg T, **Oliveira C**, Hochain P, *Karam R*, Manouvrier S, Graziadio C, Vekemans M, Hartmann A, Baert-Desurmont S, Alexandre C, Lejeune Dumoulin S, Marroni C, Martin C, Castedo S, Lovett M, Winston J, Machado JC, Attié T, Jabs EW, Cai J, Pellerin P, Triboulet JP, Scotte M, Le Pessot F, Hedouin A, Carneiro F, Blayau M, Seruca R. Cleft lip/palate and CDH1/E-cadherin mutations in families with hereditary diffuse gastric cancer. **J Med Genet. 2006** 2006 Feb;43(2):138-42. PubMed PMID: 15831593; PubMed Central PMCID: PMC2564630 [ORIGINAL MANUSCRIPT]

90. Serpa J, Mesquita P, Mendes N, **Oliveira C**, Almeida R, Santos-Silva F, Reis CA, LePendu J, David L. Expression of Lea in gastric cancer cell lines depends on FUT3 expression regulated by promoter methylation. **Cancer Lett. 2006** Oct 28;242(2):191-7. PubMed PMID: 16427187. [ORIGINAL NETWORKING MANUSCRIPT]

91. Pereira PS, Teixeira A, Pinho S, Ferreira P, Fernandes J, **Oliveira C**, Seruca R, Suriano G, Casares F. E-cadherin missense mutations, associated with hereditary diffuse gastric cancer (HDGC) syndrome, display distinct invasive behaviors and genetic interactions with the Wnt and Notch pathways in Drosophila epithelia. **Hum Mol Genet. 2006** May 15;15(10):1704-12. Epub 2006 Apr 6. PubMed PMID: 16600987. [ORIGINAL NETWORKING MANUSCRIPT]

2005

92. Velho S, **Oliveira C**, Ferreira A, Ferreira AC, Suriano G, Schwartz S Jr, Duval A, Carneiro F, Machado JC, Hamelin R, Seruca R. The prevalence of PIK3CA mutations in gastric and colon cancer. **Eur J Cancer. 2005** Jul;41(11):1649-54. PubMed PMID: 15994075. [ORIGINAL NETWORKING MANUSCRIPT]

93. Domingo E, Niessen RC, **Oliveira C**, Alhopuro P, Moutinho C, Espín E, Armengol M, Sijmons RH, Kleibeuker JH, Seruca R, Aaltonen LA, Imai K, Yamamoto H, Schwartz S Jr, Hofstra RM. BRAF-V600E is not involved in the colorectal tumorigenesis of HNPCC in patients with functional MLH1 and MSH2 genes. **Oncogene. 2005** Jun 2;24(24):3995-8. PubMed PMID: 15782118.. [ORIGINAL NETWORKING MANUSCRIPT]

94. **Oliveira C**, Velho S, Domingo E, Preto A, Hofstra RM, Hamelin R, Yamamoto H, Seruca R, Schwartz S Jr. Concomitant RASSF1A hypermethylation and KRAS/BRAF mutations occur preferentially in MSI sporadic colorectal cancer. **Oncogene. 2005** Nov 17;24(51):7630-4. PubMed PMID: 16007118. [ORIGINAL MANUSCRIPT]

95. **Oliveira C**, Moreira H, Seruca R, de Oliveira MC, Carneiro F. Role of pathology in the identification of hereditary diffuse gastric cancer: report of a Portuguese family. **Virchows Arch. 2005** Feb;446(2):181-4. Epub 2004 Dec 11. PubMed PMID: 15735979. [ORIGINAL MANUSCRIPT]

96. Gorringe KL, Chin SF, Pharoah P, Staines JM, **Oliveira C**, Edwards PA, Caldas C. Evidence that both genetic instability and selection contribute to the accumulation of chromosome alterations in cancer. Carcinogenesis. 2005 May;26(5):923-30. PubMed PMID: 15677628.. [ORIGINAL MANUSCRIPT]

2004

97. **Oliveira C***, Westra JL, Arango D, Ollikainen M, Domingo E, Ferreira A, Velho S, Niessen R, Lagerstedt K, Alhopuro P, Laiho P, Veiga I, Teixeira MR, Ligtenberg M, Kleibeuker JH, Sijmons RH, Plukker JT, Imai K, Lage P, Hamelin R, Albuquerque C, Schwartz S Jr, Lindblom A, Peltomaki P, Yamamoto H, Aaltonen LA, Seruca R, Hofstra RM. Distinct patterns of KRAS mutations in colorectal carcinomas according to germline mismatch repair defects and hMLH1 methylation status. **Hum Mol Genet. 2004** Oct 1;13(19):2303-11. Epub 2004 Aug 4. PubMed PMID: 15294875. [ORIGINAL MANUSCRIPT]

98. Domingo E, Espín E, Armengol M, **Oliveira C**, Pinto M, Duval A, Brennetot C, Seruca R, Hamelin R, Yamamoto H, Schwartz S Jr. Activated BRAF targets proximal colon tumors with mismatch repair deficiency and MLH1 inactivation. **Genes Chromosomes Cancer. 2004** Feb;39(2):138-42. PubMed PMID: 14695993. [ORIGINAL NETWORKING MANUSCRIPT]

99. **Oliveira C***, Ferreira P, Nabais S, Campos L, Ferreira A, Cirnes L, Alves CC, Veiga I, Fragoso M, Regateiro F, Dias LM, Moreira H, Suriano G, Machado JC, Lopes C, Castedo S, Carneiro F, Seruca R. E-Cadherin (CDH1) and p53 rather than SMAD4 and Caspase-10 germline mutations contribute to genetic predisposition in Portuguese gastric cancer patients. **Eur J Cancer. 2004** Aug;40(12):1897-903. PubMed PMID: 15288293. [ORIGINAL MANUSCRIPT]

100. **Oliveira C**, de Bruin J, Nabais S, Ligtenberg M, Moutinho C, Nagengast FM, Seruca R, van Krieken H, Carneiro F. Intragenic deletion of CDH1 as the inactivating mechanism of the wild-type allele in an HDGC tumour. **Oncogene. 2004** Mar 18;23(12):2236-40. PubMed PMID: 14661064. [ORIGINAL MANUSCRIPT]

101. **Oliveira C**, Suriano G, Ferreira P, Canedo P, Kaurah P, Mateus R, Ferreira A, Ferreira AC, Oliveira MJ, Figueiredo C, Carneiro F, Keller G, Huntsman D, Machado JC, Seruca R. Genetic screening for familial gastric cancer. **Hered Cancer Clin Pract. 2004** May 15;2(2):51-64. doi: 10.1186/1897-4287-2-2-51. PubMed PMID:20233471; PubMed Central PMCID: PMC2839995. [REVIEW MANUSCRIPT]

2003

102. Suriano G*, **Oliveira C***, Ferreira P, Machado JC, Bordin MC, De Wever O, Bruyneel EA, Moguilevsky N, Grehan N, Porter TR, Richards FM, Hruban RH, Roviello F, Huntsman D, Mareel M, Carneiro F, Caldas C,

Seruca R. Identification of CDH1 germline missense mutations associated with functional inactivation of the E-cadherin protein in young gastric cancer probands. **Hum Mol Genet. 2003** Mar 1;12(5):575-82. PubMed PMID: 12588804. [ORIGINAL MANUSCRIPT]

103. **Oliveira C#**, Pinto M, Duval A, Brennetot C, Domingo E, Espín E, Armengol M, Yamamoto H, Hamelin R, Seruca R, Schwartz S Jr. BRAF mutations characterize colon but not gastric cancer with mismatch repair deficiency. **Oncogene. 2003** Dec 11;22(57):9192-6. PubMed PMID: 14668801. [ORIGINAL MANUSCRIPT]
104. Suriano G, Oliveira MJ, Huntsman D, Mateus AR, Ferreira P, Casares F, **Oliveira C**, Carneiro F, Machado JC, Mareel M, Seruca R. E-cadherin germline missense mutations and cell phenotype: evidence for the independence of cell invasion on the motile capabilities of the cells. **Hum Mol Genet. 2003** Nov 15;12(22):3007-16. PubMed PMID: 14500541. [ORIGINAL NETWORKING MANUSCRIPT]
105. **Oliveira C**, Seruca R, Caldas C. Genetic screening for hereditary diffuse gastric cancer. Expert Rev Mol Diagn. 2003 Mar;3(2):201-15. Review. PubMed PMID: 12647996. [REVIEW MANUSCRIPT]
106. Pinto M, **Oliveira C**, Cirnes L, Carlos Machado J, Ramires M, Nogueira A, Carneiro F, Seruca R.J. Promoter methylation of TGFbeta receptor I and mutation of TGFbeta receptor II are frequent events in MSI sporadic gastric carcinomas. **J Pathol. 2003** 2003 May;200(1):32-8. PubMed PMID: 12692838.. [ORIGINAL NETWORKING MANUSCRIPT]
107. Carvalho B, Pinto M, Cirnes L, **Oliveira C**, Machado JC, Suriano G, Hamelin R, Carneiro F, Seruca R. Concurrent hypermethylation of gene promoters is associated with a MSI-H phenotype and diploidy in gastric carcinomas. **Eur J Cancer. 2003** Jun;39(9):1222-7. PubMed PMID: 12763209. [ORIGINAL NETWORKING MANUSCRIPT]
108. Pinto M, Wu Y, Suriano G, Mensink RG, Duval A, **Oliveira C**, Carvalho B, Hamelin R, Seruca R, Hofstra RM. MBD4 mutations are rare in gastric carcinomas with microsatellite instability. **Cancer Genet Cytogenet. 2003** Sep;145(2):103-7. PubMed PMID: 12935920. [ORIGINAL NETWORKING MANUSCRIPT]
109. Brennetot C, Duval A, Hamelin R, Pinto M, **Oliveira C**, Seruca R, Schwartz S Jr. Frequent Ki-ras mutations in gastric tumors of the MSI phenotype. **Gastroenterology. 2003** Oct;125(4):1282. PubMed PMID: 14552318. [ORIGINAL NETWORKING MANUSCRIPT]
110. Serpa J, Almeida R, **Oliveira C**, Silva FS, Silva E, Reis C, Le Pendu J, Oliveira G, Ribeiro LM, David L. Lewis enzyme (alpha1-3/4 fucosyltransferase) polymorphisms do not explain the Lewis phenotype in the gastric mucosa of a Portuguese population. **J Hum Genet. 2003**;48(4):183-9. Epub 2003 Mar 20. PubMed PMID: 12730721. [ORIGINAL NETWORKING MANUSCRIPT]

2002

111. **Oliveira C**, Bordin MC, Grehan N, Huntsman D, Suriano G, Machado JC, Kiviluoto T, Aaltonen L, Jackson CE, Seruca R, Caldas C. Screening E-cadherin in gastric cancer families reveals germline mutations only in hereditary diffuse gastric cancer kindred. **Hum Mutat. 2002** May;19(5):510-517. PubMed PMID: 11968083. [ORIGINAL MANUSCRIPT]
112. Carvalho R, Kayademir T, Soares P, Canedo P, Sousa S, **Oliveira C**, Leistenschneider P, Seruca R, Gött P, Blin N, Carneiro F, Machado JC. Loss of heterozygosity and promoter methylation, but not mutation, may underlie loss of TFF1 in gastric carcinoma. **Lab Invest. 2002** Oct;82(10):1319-26. PubMed PMID: 12379766. [ORIGINAL NETWORKING MANUSCRIPT]
113. Pharoah PD, **Oliveira C**, Machado JC, Keller G, Vogelsang H, Laux H, Becker KF, Hahn H, Paproski SM, Brown LA, Caldas C, Huntsman D. CDH1 c-160a promotor polymorphism is not associated with risk of stomach cancer. **Int J Cancer. 2002** Sep 10;101(2):196-7. PubMed PMID: 12209998. [ORIGINAL NETWORKING MANUSCRIPT]
114. Sobrinho-Simões M, **Oliveira C#**. Different types of epithelial cadherin alterations play different roles in human carcinogenesis. **Adv Anat Pathol. 2002** Nov;9(6):329-337. PubMed PMID: 12409641. [REVIEW MANUSCRIPT]

2001

115. Machado JC, Pharoah P, Sousa S, Carvalho R, **Oliveira C**, Figueiredo C, Amorim A, Seruca R, Caldas C, Carneiro F, Sobrinho-Simões M. Interleukin 1B and interleukin 1RN polymorphisms are associated with increased risk of gastric carcinoma. **Gastroenterology. 2001** Oct;121(4):823-9. PubMed PMID: 11606496. [ORIGINAL NETWORKING MANUSCRIPT]

116. Machado JC, **Oliveira C**, Carvalho R, Soares P, Berx G, Caldas C, Seruca R, Carneiro F, Sobrinho-Simões M. E-cadherin gene (CDH1) promoter methylation as the second hit in sporadic diffuse gastric carcinoma. **Oncogene. 2001** Mar 22;20(12):1525-1528. PubMed PMID: 11313896. [ORIGINAL MANUSCRIPT]

2000

117. Pinto M, **Oliveira C**, Machado JC, Cirnes L, Tavares J, Carneiro F, Hamelin R, Hofstra R, Seruca R, Sobrinho-Simões M. MSI-L gastric carcinomas share the hMLH1 methylation status of MSI-H carcinomas but not their clinicopathological profile. **Lab Invest. 2000** Dec;80(12):1915-23. PubMed PMID: 11140703. [ORIGINAL NETWORKING MANUSCRIPT]

1999

118. Caldas C, Carneiro F, Lynch HT, Yokota J, Wiesner GL, Powell SM, Lewis FR, Huntsman DG, Pharoah PD, Jankowski JA, MacLeod P, Vogelsang H, Keller G, Park KG, Richards FM, Maher ER, Gayther SA, **Oliveira C**, Grehan N, Wight D, Seruca R, Roviello F, Ponder BA, Jackson CE. Familial gastric cancer: overview and guidelines for management. **J Med Genet. 1999** Dec;36(12):873-80. PubMed PMID: 10593993; PubMed Central PMCID: PMC1734270. [REVIEW MANUSCRIPT]

1998

119. **Oliveira C**, Seruca R, Seixas M, Sobrinho-Simões M. The clinicopathological features of gastric carcinomas with microsatellite instability may be mediated by mutations of different "target genes": a study of the TGFbeta RII, IGFII R, and BAX genes. **Am J Pathol. 1998** Oct;153(4):1211-9. Review. PubMed PMID: 9777952; PubMed Central PMCID: PMC1853052. [ORIGINAL MANUSCRIPT]

BOOK CHAPTERS (n=6)

1. Carvalho J, Pinheiro H, **Oliveira C#**. "E-cadherin germline mutations" In Spotlight on Familial and Hereditary Gastric Cancer. Springer-Verlag GmbH 2013
2. Pinheiro H, Carvalho J, **Oliveira C#**. "Alternative mechanisms to germline CDH1 mutations in hereditary diffuse gastric cancer" In Spotlight on Familial and Hereditary Gastric Cancer. Springer-Verlag GmbH 2013
3. **Oliveira C#**, Pinheiro H, Figueiredo J, Seruca R, Carneiro F. "E-cadherin alterations in hereditary disorders with emphasis on hereditary diffuse gastric cancer". Prog Mol Biol Transl Sci. 2013;116:337-59. doi:10.1016/B978-0-12-394311-8.00015-7. PubMed PMID: 23481202
4. Carneiro F, **Oliveira C**, Seruca R. "Hereditary Diffuse Gastric Cancer and Other Gastric Cancers Associated with Hereditary Predisposition Syndromes". In Molecular Pathology of Neoplastic Gastrointestinal Diseases. Part II Epithelial Neoplastic Disease, Chapter 6. Page 83. Springer, 2013.
5. Velho S, **Oliveira C**, Seruca R. "PIK3CA Gene Alterations in Human Cancers". In Bioinformatics in Cancer and Cancer Therapy. Series: Cancer Drug Discovery and Development. Gordon, Gavin J. (Ed.), 2009.
6. Karam R, **Oliveira C**, Seruca R, Carneiro F. "Câncer Gástrico Hereditário". In Actualização em Câncer Gástrico. Cap 8, pag 109. Tecmedd Editora 2005.

Porto, 05 May 2018